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Background: Epidemiological evidence suggests an association between cardiovascular disease 
and environmental pollutants. Arsenic is a common contaminant in drinking water throughout the 
world, and recent studies suggest a link between inorganic arsenic (iAS) exposure and ischemic 
heart disease. Although female hearts exhibit an estrogen-dependent reduction in susceptibility to 
ischemic injury compared to males, females may be especially susceptible to iAS due to 
endocrine disrupting effects. However, iAS exposure and susceptibility to ischemic heart injury 
have not been examined in mechanistic studies. 
 
Methods: Male and female C57BL/6J mice (aged 8 weeks) were exposed to varying 
concentrations of sodium arsenite (0 parts per billion (ppb), 10ppb, 100ppb, 1000ppb) via 
drinking water for 4 weeks. Hearts were then excised and subjected to ischemia-reperfusion (I/R) 
injury via Langendorff perfusion. Pre and post-exposure echocardiography was also conducted, 
and post-exposure plasma samples were collected for 17b-estradiol measurement. 
 
Results: Mice exposed to 10ppb or 100ppb of iAs revealed no significant changes in gross 
cardiac morphology, functioning, or susceptibility to ischemia-reperfusion injury. At 1000ppb of 
iAS, female hearts exhibited modest structural remodeling with no change in heart function, 
while male hearts showed no change in cardiac morphology or function. Interestingly, we 
identified substantial sex-dependent changes in I/R susceptibility. iAS-treated female hearts 
showed a significant decrease in post-ischemic functional recovery and increased infarct size, 
while iAS-treated males showed significantly enhanced post-ischemic functional recovery and 
reduced infarct size. Assessment of plasma 17b-estradiol levels revealed a decrease in iAS-
treated females (vs. non-treated females), but this decrease was not significant. eNOS protein 
 iii 
levels were significantly decreased in whole heart homogenates from both iAS-treated male and 
female hearts. eNOS phosphorylation at Ser1177 was also significantly elevated in iAS-treated 
male hearts. 
 
Conclusions: These results suggest that an environmental exposure such as iAS, can modulate 
susceptibility to ischemic heart disease. Our results further suggest that iAS can modulate 
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Introduction and Background  
 
1.1 General introduction 
 
The cardiovascular system consists of the heart and a highly organized network of blood vessels, 
including arteries, veins, and capillaries, that serve as the blood circulation network of the body. 
The highly muscular heart generates the force necessary for the movement of blood throughout 
the body. The human heart consists of four chambers, including the right atrium, right ventricle, 
left atrium, and left ventricle. The right and left atria receive blood from veins whereas the left 
and right ventricle pump blood out of the heart through arteries. The heart pump has two sets of 
valves that maintain fluid flow in the correct direction. The two atrioventricular valves separate 
the atria from the ventricles. Two semilunar valves are located at the base of the major vessels 
joined to the ventricles. Separating the right atria and ventricle is the tricuspid valve, while the 
bicuspid valve (or mitral valve) separates the left atria and ventricle. The pulmonic valve 
separates the pulmonary truck from the right ventricle, while the aortic valve separates the aortic 
arch from the left ventricle. When the ventricles contract, termed systole, the atrioventricular 
valves close to prevent backflow of blood from the ventricles into the atria. When the ventricles 
relax, termed diastole, the semilunar valves close to prevent backflow of blood from the aortic 
arch and the pulmonary trunk into the ventricles. The cardiovascular system’s role of maintaining 
homeostasis relies on the coordinated function of the vessels, atria, and valves and the continuous 
movement of blood throughout the body in the correct direction. The circulating blood serves as 
the delivery system for essential materials as well as the mediator of cellular waste removal. 
Oxygen rich blood, required for cellular respiration, is pumped from the heart to the organs, 
penetrating the tissue through an integrative network of capillaries. Simultaneously, the blood 
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receives carbon dioxide and other waste products from cells where it can be transported to the 
kidneys and lungs and excreted from the body (Weinhaus and Roberts 2009).  
 
Numerous mechanisms underlie the functions of the cardiovascular system. Any endogenous or 
exogenous agent that disrupts the normal structure or function of the heart or the peripheral 
vessels causes cardiovascular disease. The traditionally thought of risk factors for developing 
cardiovascular disease are generally modifiable behaviors, such as smoking and physical 
inactivity. Environmental exposures are now being recognized as a major risk factor for the 
development of cardiovascular disease. In contrast to smoking and physical inactivity, individuals 
often have little control over the exposures they face during their lifetime. The heart and 
vasculature network is sensitive to a variety of environmental agents, including pesticides, metals, 
and particulate matter. This thesis focuses on the effects of inorganic arsenic on the 
cardiovascular system. Inorganic arsenic is listed by the World Health Organization as one of the 
top 10 environmental contaminants of particular concern (Cosselman et al. 2015). The metalloid 
can be found at high concentrations in contaminated ground water. Chronic exposure to inorganic 
arsenic is linked to various fatal and non-fatal cardiovascular diseases, including atherosclerosis, 
hypertension, and ischemic heart disease. The mechanism(s) by which inorganic arsenic drives 
cardiovascular disease incidence has yet to be fully understood. This chapter will introduce a 
number of concepts, including basic cardiovascular physiology and pathophysiology, the 
phenomenon of sex-dependent cardioprotection with a focus on the role of estrogen signaling, 
and arsenic cardiotoxicity according to the previously published literature.  
 
1.2 Myocardial physiology   
 
The heart has an extensive role in maintaining homeostasis in the human body. A functional heart 
supplies blood to various tissues and organs that are undergoing metabolic processes with a high 
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demand for oxygenated blood that is rich in nutrients, metabolites, and hormones. Maintaining 
homeostasis in the human body requires the heart muscle, which is composed of cardiomyocytes 
or contractile cells, to contract and relax in a synchronized and sustained manner. The 
coordinated contraction and relaxation of the myocardium is referred to as the cardiac cycle and 
is driven by the action potentials initiated spontaneously by the autorhythmic fibers in the sino-
atrial (SA) node, which is located in the wall of the right atrium. The heart muscle is unique in 
that the generation of the action potential does not require the input of the nerve stimuli like 
smooth or skeletal muscle. Instead, the SA node independently maintains the synchronized 
rhythm of the heart. While heart rate can be influenced by the sympathetic and parasympathetic 
nervous system, the SA node alone can maintain the coordinated contraction and relaxation of the 
heart muscle. The SA node also has the ability to alter the generation of action potentials to adapt 
to the changing demands of the body (Fishbein et al. 1981; Nabeebaccuus and Shah 2014). 
 
1.2.1 Cardiac cycle  
 
The cardiac cycle is initiated by the depolarization of the SA node. Cells of the SA node have a 
spontaneous gradual change in membrane potential which is referred to as diastolic depolarization 
(Li et al. 2016). The spontaneous diastolic depolarization of the SA node leads to the generation 
of an action potential referred to as the pacemaker potential. The mechanism by which the SA 
node cells spontaneously depolarize is still not fully understood. The classic mechanism of 
spontaneous depolarization is through the opening of hyperpolarization activated cyclic 
nucleotide (HCN) gated channels of the sarcolemma membrane, the opening of which allows for 
a mixed flux of sodium and potassium ions creating an inward current that is referred to as a 
funny current. The funny current allows the SA node cells to depolarize and to reach the 
threshold that allows voltage gated sodium channels to open (Joung et al. 2009). Once the action 
potential is generated by the pacemaker cells it can travel throughout both atrial chambers via the 
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gap junctions of the intercalated discs, located between the tightly packed myocardial fibers to 
allow for the contraction of both atria simultaneously. The action potential reaches the 
atrioventricular (AV) node and is slowed down to allow for both atria to fully contract and empty 
into the ventricles through the tricuspid and mitral valves. At this point, the action potential has 
not reached the ventricles, as the chambers are insulated by a surrounding fibrous skeleton. The 
action potential spreads from the AV node through the bundle of His, where it propagates through 
the septum by means of the right and left bundle branches. When the action potential reaches the 
apex of the heart, the Purkinje fibers rapidly conduct the action potential upward causing the 
ventricles to contract (Wilcken 2012). This allows for blood to be pushed up and through the 
aortic and pulmonary valves overcoming the afterload or outflow resistance of the vasculature. 
 
1.2.2 Cardiac contractile machinery  
 
The heart is comprised of cardiomyocytes that make up the majority of the hearts mass. Unlike 
skeletal muscle fibers, cardiac muscle fibers are branched and shorter in length. Cardiac muscle 
has a high number of mitochondria that are much larger than those of the skeletal muscle. This 
allows the cardiac muscle cells to meet the high energy demands of the continuous energy 
dependent contractile processes. Cardiomyocytes are tightly packed together by desmosomes and 
connected by gap junctions that allow for the rapid spread of action potentials and the 
synchronized contraction of the muscle. Because nutrients are unable to diffuse rapidly into the 
cells that make up the cardiac walls as the chambers of the heart are being perfused, the 
myocardium requires its own network of blood vessels. Two coronary arteries, the right and left 
coronaries, descend in a branching manner from the aorta towards the apex of the heart to supply 
oxygenated blood to the entire myocardium. The majority of the coronary blood supply is to the 
left ventricle and this is greatest during ventricular diastole (Nabeebaccuus and Shah 2014). 
Cardiomyocytes have a resting membrane potential of roughly -90 mV due to the leaching of 
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potassium cations through inward-rectifier potassium ion channels of the sarcolemma membrane. 
An action potential, initiated by the pacemaker cells of the SA node, will spread along the 
sarcolemma and T-tubule network of a myocyte allowing the membrane potential to reach 
threshold at roughly -70 mV initiating the opening of voltage gated fast sodium channels. This 
allows for the rapid influx of sodium down the electrochemical gradient of the interstitial fluid 
and the cytosol of the cardiomyocyte. This inflow of sodium ions results in the rapid 
depolarization of the cell membrane to slightly above 0 mV causing the sodium channels to close 
(Nabeebaccuus and Shah 2014). During this depolarization, voltage gated L-type calcium 
channels open and a steady influx of calcium occurs down the concentration gradient into the 
cytosol of the myocytes. This inflow of calcium cations stimulates additional calcium ions to be 
released from the sarcoplasmic reticulum, which is the major calcium store in the cardiomyocyte, 
into the cytosol through the sarcoplasmic reticulum calcium release channel (or ryanodine 
receptor, RyR) (Wang et al. 2008). This calcium-induced calcium release is required for muscle 
contraction, as the initial calcium influx is insufficient to meet contractile requirements. The 
contractile machinery is stimulated by the binding of calcium to troponin-C (Winslow et al. 
2016). The proteins of the troponin complex consist of three globular subunits that allow for its 
regulatory function. The troponin complex simultaneously binds to actin, couples to adjacent 
tropomyosin strands that conceal myosin binding sites on actin, and presents a binding site for 
calcium. The sarcomere contractile unit contains thick filaments composed of the protein myosin 
and thin filaments composed of actin. The binding of calcium to troponin drives a conformational 
change in the troponin-tropomyosin complex to reveal myosin binding sites on the thin filaments 
of actin. Muscle contraction is initiated by the binding of ATP to myosin. ATP is hydrolyzed to a 
phosphate ion and ADP and cross bridge formation occurs between actin and the myosin head. 
The accumulation of cross bridges drives a power stroke, characterized by the shortening of the 
sarcomere in which the thin and thick filaments have an increased region of overlap. This state of 
the sarcomere is maintained until another ATP binds to the myosin head. The above description 
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of muscle contraction is referred to as the sliding filament theory of muscle contraction. The 
theory was developed by Hugh Huxley and Jean Hanson in 1954 and is still universally accepted 
as the mechanism of muscle contraction (Huxley and Niedergerke 1954; Huxley and Hanson 
1954). The period of time that contraction occurs is referred to as the plateau phase. During this 
time, the influx of calcium ions is balanced with an outflow of potassium ions maintaining a 
stable depolarized electrical potential. After contraction, calcium dissociates from troponin-C and 
repolarization of the myocyte occurs through the outflow of potassium ions through various 
potassium ion channels of the sarcolemma. Relaxation of the muscle occurs as calcium is 
extruded from the cell or re-sequestered into the sarcoplasmic reticulum and the potassium efflux 
restores the myocytes electrical potential to the resting potential of -90 mV. Maintaining steady 
state calcium homeostasis is critical for proper myocyte relaxation. Steady state calcium 
homeostasis is only maintained when the amount of calcium entering the cell along with 
contraction through L-type channels equals the amount of calcium extruded from the cell before 
the subsequent contraction. The resting calcium gradient across the sarcolemma and the available 
intracellular calcium store of the sarcoplasmic reticulum directly correlates with the force of 
contraction of the myocyte. Chemical agents that alter calcium homeostasis also alter the force of 
contraction of the myocyte and thus the force generated by the heart (Barry and Bridge 1993). 
After restoring calcium homeostasis, sarcolemma repolarization, and the completion of the 
absolute refractory period the cardiomyocyte can respond to another action potential propagating 
though the heart (Nabeebaccuus and Shah 2014). 
 
1.3 Cardiovascular pathology  
 
Cardiovascular disease refers to the diseases of the heart and blood vessels. This includes but is 
not limited to congestive heart failure, atrial fibrillation, high blood pressure, stroke, and ischemic 
heart disease, also referred to as coronary heart disease. Of all the cardiovascular diseases, 
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ischemic heart disease is the most common cause of death worldwide claiming an estimated 8.91 
million lives in 2015 according to the Global Burden of Disease Study (Roth et al. 2017). In the 
early 2000s advancements in biomedical research and technology allowed for great strides in the 
effective treatment of heart disease. Heart related mortality rates declined by an average of 3.7 
percent per year from the year 2000 to 2011. In the last few years this trend has reversed as the 
risk factors for heart disease in the American population have rapidly increased. The American 
Heart Association reports that in the year 2015 the mortality rate for heart disease increased by 1 
percent for the first time since the year 1969. A 2011 review from the American Heart 
Association predicted that roughly 40 percent of the American population would suffer from 
cardiovascular disease by 2030. The organization has now recalculated the projection as the early 
estimate was surpassed in 2015 with a cardiovascular disease prevalence of 41.5 percent of the 
American population. The American Heart Association now estimates that 45 percent of the 
American population will suffer from cardiovascular disease by 2035 (Benjamin et al. 2017). 
 
1.3.1 Environmental determinants of cardiovascular disease 
 
Despite national efforts to improve cardiovascular health, the prevalence and control of 
cardiovascular risk factors in the United States remains a major issue. The persistent growth in 
the risks of cardiovascular disease exemplifies our lack of a complete understanding of the 
underlying risk factors contributing to the growing burden of heart disease hindering effective 
prevention and treatment (Benjamin et al. 2017). Existing research suggests that the majority of 
cardiovascular disease is preventable highlighting the environmentally driven nature of heart 
disease. Less well understood is how environmental risk factors influence heart disease. Rates of 
cardiovascular disease differ drastically  among different populations of different geographical 
regions (Willett 2002). The mortality rates for cardiovascular disease are roughly 7 to 14 times 
higher in Northern and Eastern Europe when compared to other countries including Japan and 
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Argentina (Levi et al. 2002). Migrant studies indicate that when groups move from low to high 
risk countries, their disease rates begin to resemble the populations of the new environment 
(Bhatnagar et al. 1995; Patel et al. 2006; Worth et al. 1975). Epidemiological analysis suggests 
that changes in the environment and life style factors such as nutrition and exercise could 
decrease the incidence of coronary artery disease by roughly 80 percent and stroke incidence by 
70 percent (Willett 2002). Generating a complete understanding of cardiovascular disease 
therefore requires an approach that utilizes the disciplines of the environmental sciences and 
cardiology. Numerous epidemiological studies have provided direct links between heart disease 
and exposure to common environmental pollutants like particulate matter, metals, and toxic gases 
but the extent at which these pollutants contribute to the manifestation of the diseases remains 
unclear. The toxicopathological mechanisms by which environmental pollutants drive different 
forms of heart disease have yet to be fully identified (O'Toole et al. 2008). An expansion upon 
our knowledge on the underlying mechanism by which environmental pollutant exposures drive 
the manifestation of cardiovascular disease is essential for the development of effective treatment 
options and population prevention techniques for heart related diseases.  
 
1.3.2 Ischemia-reperfusion injury 
 
Myocardial ischemia, the imbalance of cardiac blood supply and demand, is the main clinical 
symptom of ischemic heart disease. Myocardial infarction results from periods of myocardial 
ischemia driven primarily by the occlusion of the coronary arteries that sit on the epicardial 
surface of the heart. Myocardial ischemia occurs when the blood flow to the heart is reduced or 
lost and the myocardium is subjected to a prolonged period of anoxia and nutrient deprivation. 
The heart requires an immense amount of oxygen to meet the aerobic metabolic needs of the 
mitochondria in cardiomyocytes. The electron transport chain is hindered by the lack of oxygen, 
leading to a drastic decline in ATP levels and the disruption of cytoplasmic ion concentrations as 
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the sarcolemmal Na+/K+ ATPase and the sarcoplasmic reticulum Ca2+ ATPase can no longer 
mitigate active transport of ions. This results in elevated levels of cystolic calcium and sodium in 
the myocyte and dysfunction in the calcium driven contractile machinery. The diminishment of 
oxidative phosphorylation drives an increase in anaerobic respiration and an accumulation of 
lactic acid. Proton concentrations rise rapidly, lowering the intracellular pH and inhibiting the 
glycolytic enzyme activity further exacerbating the diminished levels of ATP. High proton 
concentrations also drive the cellular import of sodium ions through the Na+/H+ Transporter of 
the sarcolemma. To compensate for high sodium levels, the cell reverses the activity of the 
Na+/Ca2+ exchanger resulting in a further overload of cystolic calcium levels. Elevated levels of 
cystolic calcium disrupts the normal synchronized pattern of myocyte contraction. Additionally, 
calcium overload initiates various non-caspase proteases that are implicated in apoptosis and 
necrosis including calpain and cathepsins. Without timely reperfusion the profound cellular 
dysfunction results in irreversible myocardial infarction and a loss in overall heart function. 
While reperfusion therapies are necessary to restore blood flow to the ischemic myocardium to 
retrieve functional heart tissue, the intervention results in additional cardiac injury due to the 
many complications associated with the abrupt reperfusion of the coronary artery flow. During 
ischemia moderate levels of superoxide dismutase are produced in response to the oxidative 
stress. With the onset of reperfusion there is a burst of mitochondrial derived reactive oxygen 
species (ROS) production and the saturated superoxide dismutase is unable to compensate. 
Elevated cellular ROS levels, accompanied by calcium overload, leads to mitochondrial induction 
of apoptotic and necrotic cellular pathways. ROS, calcium overload, ionic imbalance, reduced 
ATP production, and lowered pH all appear to be factors implicated in the cardiomyocyte death 
associated with the Ischemia-reperfusion injury. Ischemia-reperfusion injury has been observed to 
be extremely time sensitive. The extent of injury is directly proportional to the length of the 
ischemic period. While 5 minutes of ischemia can result in slight cardiac arrhythmias, periods of 
ischemia greater than 20 minutes can lead to irreversible necrosis or apoptosis (Powers et al. 
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2007). The infarcted heart tissue lacks contractility and prevents the heart from appropriately 
functioning as the blood pump of the body. 
 
1.3.3 Cardiac remodeling    
 
Cardiac remodeling is either physiological or pathological and describes the changes in size, 
shape or function of the myocardium that results from internal or external stimuli that cause 
biological or mechanical stress. Cardiac remodeling can be either a beneficial result of regular 
exercise or a maladaptive response to various chronic stressors, including pressure overload, 
volume overload, or myocardial infarction. Increased fluid volume or pressure incident on the 
heart chambers results in a stretching force on the myocardium. Stretching caused by the 
increased work load results in a hypertrophic response, or growth in size of the cardiomyocyte. In 
response to normal physiological stress, cardiomyocytes respond with the synthesis of new 
contractile proteins and the formation of new sarcomeres aligned in a highly organized parallel 
manner. This type of remodeling, termed physiological hypertrophy, is reversible and allows for 
the generation of greater force with each contraction. In response to chronic stress, irreversible 
remodeling occurs. Pathological hypertrophy is characterized by the elevated and 
disproportionate contribution of cardiac fibroblasts, which produce excessive amounts of collagen 
leading to fibrosis and the stiffing of the myocardium. Myocytes are eventually replaced with 
more fibroblasts and extracellular collagen. With prolonged pathological cardiac remodeling, the 
heart losses the ability to undergo hypertrophy and to adapt to changing fluid volumes and 
pressures (Frey and Olson 2003; Mihl et al. 2008). High blood pressure is considered the most 
important risk factor for cardiac remodeling and heart failure. The cardiac hypertrophy of 
hypertensive patients is a response to the afterload that results from the stiffening of the vessels. 
In the case of ischemic injury and myocardial infarction, cardiomyocytes must grow in size to 
assume the work of the heart segment that was lost (Burchfield et al. 2013).  
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1.3.4 ROS and oxidative stress 
 
When examining cardiac injury as it relates to an environmental stressor like arsenic exposure, it 
is important to consider the effects of ROS. ROS includes superoxide, hydrogen peroxide, and the 
highly reactive hydroxyl radical. It is well known that an increase in ROS is directly associated 
with ischemia-reperfusion injury. ROS are generated from multiple sources including the 
mitochondrial electron transport chain, xanthine oxidase, and NADPH oxidase (phagocyte 
oxidase) (Figure 1). The mitochondrial generation of ROS is recognized as the primary 
contributor to ischemia-reperfusion related oxidative stress. It is estimated that roughly 95% of 
oxygen is reduced to water through the mitochondrial electron transport chain. The remaining 5% 
of oxygen cycling through the electron transport chain generates the highly reactive superoxide 
anion.  Xanthine oxidase is a mammalian redox enzyme with relatively low specificity as it 
catalyzes the reduction of a number of species including oxygen, cytochrome c, and nitric oxide 
(Pacher et al. 2006). The NADPH oxidase is a neutrophil enzyme that catalyzes the production of 
superoxide from molecular oxygen (Segal 2008). At low levels, ROS may have protective roles 
via signaling for preconditioning or through oxidant induced gene transcription. Under normal 
conditions, our tissues have a specialized system which is sufficient for keeping ROS levels low, 
thereby preventing extensive oxidative damage by an overabundance of superoxide radicals and 
other ROS. Superoxide dismutase (SOD) reduces superoxide to the less reactive hydrogen 
peroxide. The hydrogen peroxide is further reduced to water by the enzyme catalase or through 
the glutathione peroxidase system (Figure 1) (Becker 2004). Transgenic mice overexpressing 
manganese superoxide dismutase (SOD2), the SOD enzyme isoform restricted to the 
mitochondrial matrix and functioning to reduce ROS levels within the mitochondria, were 
observed to be protected against myocardial ischemia-reperfusion injury. This provides 
substantial evidence that the oxidative stress implicated in the injury is largely due to 
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mitochondrial derived ROS rather than from exogenous sources of ROS (Powers et al. 2007). 
When oxidant scavenging systems are saturated and hydrogen peroxide concentrations are 
elevated within the cell, hydrogen peroxide can react with metal ions via the Fenton reaction to 
form the highly reactive and destructive hydroxyl radical. Hydroxyl radicals readily oxidize 
lipids, DNA, and proteins (Figure 1) (Becker 2004). Considering the role of the mitochondria in 




Figure 1. ROS production and metabolism (Becker 2004). 
 
1.3.5 Mitochondrial ROS generation 
 
The mitochondria is the driver of metabolism within the cell, generating the majority of the ATP 
necessary for a variety of cellular processes in the myocyte, including active transport 
mechanisms, as well as the coordinated contraction and relaxation of the cardiomyocyte 
machinery. Mitochondria play a central role in ROS related molecular pathology. During 
ischemia, the mitochondria becomes compromised due to the stressful hypoxic conditions which 
include calcium overload, an acidic pH, disrupted ion concentrations, and rapid ATP depletion. 
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When the ischemic tissue is reperfused, damaged mitochondria leak electrons from a number of 
locations on to molecular oxygen to form superoxide. This description of mitochondrial ROS 
production is an overly simplified explanation that does not encompass the highly complex nature 
of ROS generation. The true mechanism of mitochondrial ROS production has not been fully 
developed. However, Complex I and complex III of the electron transport chain have been 
identified as the major sites of ROS generation under stressful conditions (Murphy 2016).  
 
1.3.6 Cardiomyocyte death 
 
Mitochondria can become damaged by endogenous and exogenous ROS, leading to necrosis and 
apoptosis, which occurs through a variety of cellular pathways. Elevated ROS levels in the cell, 
accompanied by calcium overload, can lead to an increase in the inner or outer mitochondrial 
membrane permeability and the induction of apoptotic and necrotic cellular pathways. The two 
pathways leading to cellular apoptosis are called the extrinsic and intrinsic pathways. The 
extrinsic pathway occurs in the cytosol through the ligation of death receptors that drive the 
formation of the Fas-associating death domain-containing protein (FADD) oligomer located 
within the death inducing signaling complex (DISC). FADD causes the dimerization and 
activation of the initiator caspases 8 and 10. The initiator caspases cleave and activate the effector 
caspases of the proteasome and thereby trigger apoptotic cell death through the cleavage of 
specific substrates in the cell (Parrish et al. 2013). The intrinsic pathway is driven by the 
mitochondria and is the pathway implicated in ischemia-reperfusion injury. The combination of 
ischemia and reperfusion induces the translocation of pro apoptotic proteins of the Bcl-2 family 
from the cytosol to the outer membrane of the mitochondria. The Bcl-2 proteins bind to the outer 
membrane and increase the permeability of the membrane, which allows for the release of 
apoptotic proteins from the inner membrane space. The primary apoptotic protein implicated in 
the intrinsic cascade of cellular apoptosis is cytochrome c. Cytochrome c and the presence of 
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ATP allows for the activation of the adapter molecule apoptosis protease activating factor 1 
(APAF-1) within the apoptosome multiprotein complex. The apoptosome can then activate the 
effector caspases that trigger apoptotic cell death through the cleavage of specific substrates in the 
cell. In addition to the release of cytochrome c, Smac/DIABLO, htrA2/omi protease, and 
Endonuclease G are released from the mitochondrial inner membrane space. The Smac/DIABLO 
and htrA2/omi proteins activate the effector caspases through the degradation of caspase 
inhibitory proteins. Endonuclease G is responsible for DNA fragmentation in the nuclease 
(Baines 2009). The apoptotic proteins collectively drive the death of the cardiomyocyte. 
Cardiomyocyte death is particularly problematic in mammalian species due to the lack of 
proliferation of adult cardiomyocytes. Cardiomyocytes rapidly proliferate during fetal life but 
lose this ability soon after birth with the withdrawal from the cell cycle. Cardiomyocytes are 
referred to as terminally differentiated because the cells are generally unable to reenter the cell 
cycle. Although the extent to which the adult mammalian cardiomyocyte is able to reenter the cell 
cycle is debated, most cardiac growth occurs through hypertrophy (Ahuja et al. 2007; Senyo et al. 
2014). 
 
1.3.6.1 Mitochondrial permeability transition 
 
In addition to the intrinsic and extrinsic pathways of apoptosis, both cellular necrosis and 
apoptosis are believed to be driven by the induction of the mitochondrial permeability transition 
(MPT). Excessive ROS and calcium overload in the mitochondrial matrix associated with 
reperfusion leads to the opening of a large inner membrane pore called the mitochondrial 
permeability transition pore (MPTP). The opening of the pore causes the loss of the proton 
electrochemical gradient across the inner membrane, disrupting ATP generation and inducing 
additional ROS generation. With the opening of the pore, selectivity across the inner membrane is 
lost. The mitochondrial stress can lead to the mitochondrial matrix swelling and the rupture of the 
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organelle, the release of apoptotic proteins, and cellular apoptosis by the intrinsic pathway. 
Because apoptosis requires the presence of ATP, severe ATP depletion from the mitochondrial 
permeability transition can instead result in cellular necrosis. The balance between ATP depletion 
from the MPT and the generation of ATP from glycolysis is what determines whether the cell 
death will result from apoptosis or necrosis (Kim et al. 2003). Due to the MPTP’s central role in 
both apoptosis and necrosis, the MPTP is believed to be an important target for cardioprotection. 
Pre-conditioning with specific MPTP inhibitors has been shown in both animal and clinical 




With myocardial ischemia-reperfusion injury being a major cause of morbidity and mortality in 
the world, cardioprotective strategies have great potential for reducing a significant health care 
burden (Schwartz Longacre et al. 2011). The prognosis after a myocardial ischemic injury is 
primarily dependent on myocardial infarct size. Cardioprotection refers to the strategies that are 
employed to limit myocardial infarct generation resulting from both the ischemic event and the 
related reperfusion injury. Cardioprotection can be achieved through a variety of interventions 
ranging from ischemic preconditioning, the treatment with multiple periods of brief ischemia, to 
the usage of pharmacological agents. Acute cardioprotective effects are believed to be generated 
through complex cascades of cellular signaling pathways that dictate protein expression and 
activity. There are three potential time points for a clinical intervention during an ischemic event 
referred to as pre, per, and post conditioning.  Preconditioning refers to the cardioprotection 
strategies that are implemented before an ischemic event, while perconditioning refers to the 
strategies employed during an ischemic event. Lastly, postconditioning refers to the strategies 
employed after the ischemic event and at the onset of reperfusion (Heusch 2015). Preconditioning 
with multiple periods of brief ischemia remains as one of the most powerful methods for reducing 
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myocardial infarct size. Ischemic preconditioning is however impractical for addressing an 
unpredictable acute injury in the clinical setting. There is a need to develop pharmacological 
strategies that mimic the beneficial effects gained from ischemic preconditioning (Schwartz 
Longacre et al. 2011). Our group and others have demonstrated that there is a significant increase 
in a cysteine-based post translational modification, S-nitrosylation (SNO), with multiple models 
of cardioprotection (Kohr et al. 2011a; Kohr et al. 2011b; Kohr et al. 2012; Kohr et al. 2014; 
Lochner et al. 2000; Shao et al. 2016; J Sun et al. 2006). The cysteine-based post-translational 
modification of SNO is a specific and reversible modification formed through the covalent 
attachment of nitric oxide (NO) to thiol groups. NO holds promise as a critical component of 
cardioprotection through the cellular signaling mechanism of SNO.  
 
1.3.8 Nitric oxide as a cardioprotective agent  
 
NO is a gaseous free radical signaling molecule that is heavily implicated in cellular signaling 
processes within the cardiovascular system. Of the RNS, NO is the most reactive species. NO is 
involved in both autocrine and paracrine cellular signaling, being able to diffuse across cellular 
membranes of all cell types. Since the identification of NO as the endothelium derived relaxing 
factor (EDRF) and as a physiological regulator of blood pressure, NO has become one of the 
most important signaling molecules in the cardiovascular system. The discovery of NO provided 
a clear understanding of the  mechanism of nitroglycerine, which has been administered for the 
treatment of angina symptoms since the beginning of the 20th century (Strijdom et al. 2009). 
Initially it was thought that NO could serve only as a regulator of blood pressure. After being 
validated as a cellular signaling molecule, NO has become recognized as being involved in 
numerous physiological processes including the immune response, transcriptional regulation, 
metabolism, apoptosis, and neural transmission (Forstermann and Sessa 2012)  
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1.3.8.1 Nitric oxide molecular targets and cellular signaling 
 
NO interactions can be characterized by NO’s four primary molecular targets. NO can interact 
with metals like iron and copper, forming metal-nitrosyl-complexes. NO’s interaction with metals 
can have profound effects on enzyme activity as many biological enzyme active sites contain 
metal prosthetic groups that are necessary for carrying out catalytic functions (Cooper 1999; 
Mingos 2014). NO readily reacts with superoxide radicals to form a highly reactive peroxynitrite 
radical species. Peroxynitrite radical formation can lead to the nitration of the amino acid tyrosine 
(Moreira et al. 2016; Valez et al. 2012). This interaction is important when examining the nitroso-
redox equilibrium, as tyrosine nitration can be a marker for high peroxynitrite levels in the cell 
and indicative of nitrositive stress (Peluffo and Radi 2007). NO reacts with thiols and in 
particular, the thiols of cysteine amino acid residues. Cysteine nitrosylation is an important post 
translational modification that regulates protein functions in the cell. The reversible nature of 
cysteine nitrosylation allows NO to act as a key signaling molecule (Martinez-Ruiz and Lamas 
2007; JH Sun et al. 2006). Lastly, the NO free radical can react with oxygen or carbon dioxide to 
form the less reactive, but more stable nitrite (NO2-) and nitrate (NO3- ) species. The reversible 
nature of this reaction allows nitrate and nitrite to be an important source of NO as both species 
can be reduced back to NO under specific physiological conditions (Lundberg et al. 2008). NO 
signaling occurs through two distinct mechanisms, cGMP dependent and cGMP independent. The 
role of NO was first discovered through the cGMP dependent mechanism which refers to the NO 
mediated activation of soluble guanylyl cyclase (sGC) in vascular smooth muscles cells. 
Activation of soluble guanylyl cyclase allows for the catalytic conversion of guanosine 5’- 
triphosphate (GTP) to cyclic guanosine 3’,5’- monophosphate (cGMP) in the presence of a 
magnesium cofactor. After the initial discovery of NO signaling, the cGMP dependent 
mechanism was believed to be NO’s sole mechanism of cellular signaling. NO has since been 
 18 
recognized to have the ability to act as a cell signaling molecule independent of cGMP through 
the transient post-translational modification of SNO (Tuteja et al. 2004).  
 
1.3.8.2 Sources of nitric oxide  
 
NO is either produced by the enzyme nitric oxide synthase (NOS) from L-arginine and molecular 
oxygen or by NOS-independent mechanisms through the reduction of nitrites and nitrates. Three 
distinct isoforms of NOS function as the primary source of NO within the myocardium (Barouch 
et al. 2002). NOS is an oxidoreductase enzyme that functions to produce NO through the 
oxidative conversion of L-arginine to L-citrulline. The overall reaction consists of a two-step 
oxidative conversion of L-arginine to NO and L-citrulline with NW-hydroxy-L-arginine as an 
intermediate and NADPH as an electron donating cofactor (Figure 2) (Aktan 2004). As a dimer 
consisting of two identical subunits, the enzyme properly functions to produce NO. Each subunit 
consists of two distinct domains, the C-terminal reductase domain and the N-terminal oxygenase 
domain. The C-terminal reductase domain contains binding sites for the nicotinamide adenine 
dinucleotide phosphate (NADPH), flavin adenine dinucleotide (FAD), and FMN reduction 
coenzymes necessary for full redox function. The N-Terminal oxygenase domain contains 
binding sites for heme, tetrahydrobiopterin (BH4), and the L-arginine substrate. Located between 
both terminal domains is a calmodulin binding site that functions to regulate enzyme activity 
(Alderton et al. 2001). Three NOS isoforms exist of which two are constitutively expressed in the 
cell and one, as an element of the immune system, is induced during periods of stress including 
infection. The two constitutively expressed isoforms, endothelial NOS (eNOS) and neuronal NOS 
(nNOS), require calcium for activation. Intracellular calcium binds to calmodulin forming a 
complex which can then bind to eNOS or nNOS at the calmodulin binding site, inducing a 
conformational change that activates the NOS isoform. The other isoform, inducible NOS 
(iNOS), is present at high levels only when cytokines or other inflammatory agents induce 
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expression. The inducible isoform functions independent of intracellular calcium activation as 
calmodulin is always bound to the dimer with or without calcium present (Andrew and Mayer 
1999). While Inducible NOS is only present under specific conditions, iNOS has the ability to 
produce much greater amounts of NO than the constituently expressed isoforms of NOS (Aktan 
2004). The NOS-independent mechanism of NO production is termed the nitrate-nitrite-NO 
pathway. The ability for nitrates and nitrites to be reduced to NO allows for an individual’s diet to 
serve as a key source of NO. Diets suggested to be protective against cardiovascular disease, like 
the Mediterranean diet, are rich in inorganic nitrates. Leafy green vegetables contain particularly 
high levels of nitrates that can serve as substrates for NO production mechanisms (Capurso et al. 
2014). Bacteria in the gut and oral cavity can convert nitrates to nitrites via the bacterial nitrate 
reductase enzymes (Tiso and Schechter 2015).  
 
Figure 2. Nitric oxide synthase catalyzed conversion of L-arginine to L-citruline and nitric oxide 
(Aktan 2004). 
 
1.3.8.3 Nitroso-redox equilibrium and cardiovascular health 
 
Within the cell, there is a balance between the production of ROS and the production of reactive 
nitrogen species (RNS) that is termed the nitroso-redox equilibrium, and this equilibrium appears 
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to be extremely important in maintaining cellular homeostasis. At moderate levels, both ROS and 
RNS are involved in cell signaling pathways. It is evident that the disruption of the nitroso-redox 
balance contributes to ischemia-reperfusion injury and many forms of cardiovascular disease. 
Cellular stress occurs at both high levels of ROS and high levels of RNS. Considering the 
interaction between ROS and RNS is crucial when examining an environmental pollutant’s 
toxicophysiological effects on the cardiovascular system. Various forms of cardiac dysfunction 
have been linked to reduced levels of active NOS, which can be caused by a decrease in the 
transcriptional and translational expression of NOS or from the uncoupling of the NOS dimer. 
NOS uncoupling occurs most often when the cofactor BH4 is depleted, which leads to the 
catalysis of superoxide production rather than NO production (Silberman et al. 2010). NOS can 
also be activated or inactivated through post-translational modification, including 
phosphorylation, acetylation, acylation, and s-nitrosylation (Qian and Fulton 2013; Sharma and 
Patel 2017). The upregulation of NO signaling and protein SNO is believed to be cardioprotective 
by altering the function and stability of proteins and by protecting thiol groups from the oxidative 
damage resulting from excessive ROS levels characteristic of ischemia-reperfusion injury (Kohr 
et al. 2011b; Kohr et al. 2014; Zweier and Talukder 2006). Excessive accumulation of SNO may 
exaggerate myocardial injury. There appears to be a threshold at which the protection from SNO 
is lost and nitrositive stress is triggered. In addition to the regulation of SNO levels by changes in 
expression and activation of NOS, SNO levels are regulated by S-nitrosoglutathione reductase 
(GSNOR) (Foster et al. 2012; Liu et al. 2004; Sips et al. 2013). NO can react with the antioxidant 
glutathione (GSH) to form S-nitrosoglutathione (GSNO). GSNO acts as a reservoir of NO in the 
cell and serves as a donor in the direct transfer of NO from the antioxidant to another protein 
referred to as trans-S-nitrosylation. GSNOR regulates SNO levels in the cell by catalyzing the 
conversion of GSNO to GSH (Liu et al. 2004). The maintenance of SNO levels within the 
cardiomyocyte appears to be a critical component for cardiac function. Females are believed to 
have an endogenous mechanism for the regulation of the nitroso-redox equilibrium during 
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ischemia-reperfusion injury. Understanding the cellular signaling basis of the female’s innate 
resilience to ischemia-reperfusion injury will provide insights into how to better prevent 
irreversible myocardial infarct generation from an ischemic event.  
 
1.4 Sex-dependent cardioprotection  
 
Early epidemiological studies of cardiovascular disease focused on males, working under the 
assumption that the findings could be extrapolated to the management of heart disease in women. 
That assumption has since been proven to be incorrect as many longitudinal studies 
distinguishing women from men have illuminated the lower risk of cardiovascular injury for 
premenopausal women. The incidence of heart disease is shown to  drastically increase with the 
onset of menopause (Hayward et al. 2000). It is evident that there are significant physiological 
differences between male and female hearts that contribute to the differences in the onset and 
presentation of cardiovascular disease. Because of these differences, the risk factors for coronary 
heart disease are weighted differently for women than men. At younger ages, smoking is much 
more detrimental on health status for women than men. By observing the age of onset of acute 
myocardial infarction compared to the individuals smoking habits, it has been observed that 
women lose approximately twice as many life years from smoking than men do (Grundtvig et al. 
2009). While cardiovascular disease occurs much later in women than in men, an estimated 7 to 
10 years later, heart disease remains the leading cause of death in women (Maas and Appelman 
2010). Understanding the basis of this lower incidence of heart disease in females could provide 
insights into how to better treat and manage heart disease in both females and males.   
 
A current hypothesis that is actively being investigated is that endocrine and paracrine estrogen 
signaling is at the root of the sex-dependent cardioprotection phenomenon (Hale et al. 1996; 
Hisamoto et al. 2001; Nikolic et al. 2007; MJ Wang et al. 2006). By assessing the reproductive 
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hormone levels of individuals being screened for heart disease, the NHLBI Women’s Ischemia 
Syndrome Evaluation (WISE) study showed that premenopausal women experiencing coronary 
artery disease presented with significantly lower levels of estradiol and follicle stimulating 
hormone (FSH) than women without coronary artery disease (Bairey Merz et al. 2003). The 
cardioprotective role of estrogen is still heavily debated as hormone replacement trials for 
postmenopausal women have had negative outcomes. The large randomized Women’s Health 
initiative controlled trial for estrogen-progesterone replacement therapy for postmenopausal 
women was stopped after roughly 6 years of follow up due to an observed increased risk of 
developing breast cancer which exceeded any cardioprotective benefits gained from the estrogen-
progesterone treatment (Rossouw et al. 2002). A better understanding of estrogen mediated 
protection in animal models is required before a successful translation to a clinical therapy can be 
made as an adverse outcome of breast cancer cannot be ignored.  
 
Sex-dependent protection from cardiovascular disease has been observed through numerous 
animals studies. Female animals are observed to have an improved post-ischemic functional 
recovery and smaller infarct size following ischemia-reperfusion injury when compared with 
males (Bae and Zhang 2005; Johnson et al. 2006). An abolishment of female cardioprotection to 
ischemia-reperfusion injury is observed in ovariectomized mice, further strengthening the theory 
of estrogen mediated cardioprotection (Ross and Howlett 2012). 
 
1.4.1 The physiological role of estrogen and estrogen receptors 
 
Estrogen is the female sex hormone that drives various physiological effects by binding to the 
estrogen receptors alpha and beta. The nuclear estrogen receptors act as ligand gated transcription 
factors. The nuclear estrogen receptors remain in transcriptionally inactive states in a complex 
with different nuclear chaperones when the estrogen ligand is not present. An estrogen receptor is 
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kept in its inactive state by various heat shock proteins. Upon binding of the estrogen ligand, the 
heat shock proteins dissociate from the receptor leading to the activation of the estrogen receptor 
(LeBlanc et al. 2009). Once activated, estrogen receptors have multiple modes of action. Ligand 
activated estrogen receptors can bind directly to estrogen response elements in DNA driving 
transcription of different genes. An estrogen receptor can also be activated independent of ligands 
via post translational modifications like phosphorylation. Activated estrogen receptors can 
facilitate protein-protein interactions of other transcription factors and indirectly affect regulation 
of genes that do not contain estrogen response elements. In addition to the transcriptional 
regulation of genes, estrogen and ligand activated estrogen receptors can drive cellular signaling 
through the activation of kinases and phosphatases, and by dictating ion fluxes across cellular 
membranes (Heldring et al. 2007).  
 
1.4.2 Estrogen mediated cardioprotection  
 
Several animal studies have shown estrogen and the activation of the estrogen receptors to be 
cardioprotective during ischemia-reperfusion injury (Booth et al. 2005; Hale et al. 1996; 
Lagranha et al. 2010; Lin et al. 2009a; M Wang et al. 2006). Estrogen is traditionally thought to 
be cardioprotective through the activation of estrogen receptors and the upregulation of proteins. 
In addition to the genomic effects, estrogen has been observed to drive rapid short term effects in 
the heart through the activation of various signaling pathways. Estrogen can illicit these rapid 
cardioprotective effects by binding to extra-nuclear estrogen receptors that are coupled to kinases. 
Both estrogen receptor-a (ERa) and estrogen receptor-b (ERb) have extra-nuclear actions 
involving the activation of kinases and subsequent acute signaling pathways (Menazza and 
Murphy 2016; Wu et al. 2011). Estrogen can also activate acute signaling cascades by binding to 
the transmembrane G-protein coupled receptor (GPR30) which is a localized at the plasma 
membrane of the cell (Haas et al. 2007; Revankar et al. 2005). While it is recognized that 
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estrogen is cardioprotective in the setting of ischemia-reperfusion injury, the exact estrogen 
mediated signaling mechanisms have yet to be fully developed. 
 
1.4.3 Estrogen and nitric oxide signaling 
 
The junction between estrogen and NO cell signaling pathways appears to have a major role in 
the intrinsic cardioprotection that is exhibited in premenopausal women. Estrogen is known to 
induce expression and phosphorylation of eNOS in both vascular endothelial cells and 
cardiomyocytes. Expression and activation of eNOS by estrogen is believed to be mediated 
primarily through ERa in vascular endothelial cells and through ERb in cardiomyocytes (Cross et 
al. 2002; Lin et al. 2009b; Nuedling et al. 2001; Tan et al. 1999).  
 
1.4.3.1 PI3K/Akt pathway  
 
Preclinical studies have demonstrated cardioprotection with estrogen replacement in 
ovariectomized mice through the activation of the phosphatidylinositol 3-kinase (PI3K)-Akt 
pathway (Figure 3) (Patten et al. 2004). The PI3K/Akt pathway is a component of the 
Reperfusion Injury Salvage Kinase (RISK) pathway. The RISK pathway encompasses a group of 
pro-survival protein kinases that when activated, provide protection in the setting of ischemia-
reperfusion injury. The RISK pathway includes many other cardioprotective salvage kinases 
including Erk1/2, JNK, PKC, PKG, p70s6K, and GSK-3b. Estrogen has been shown to increase 
the phosphorylation and activation of eNOS in the myocardium by binding to a membrane bound 
estrogen receptor which is believed to be coupled to PI3K (Guo et al. 2006; Hisamoto et al. 
2001). Activated PI3K phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) to generate 
phosphatidylinositol-3,4,5-bisphosphate (PIP3). The membrane bound PIP3 serves as a binding 
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site for Akt (also known as Protein Kinase B or PKB), which exists as one of three isoforms 
(Akt1, Akt2, and Akt3). Each isoform contains an N-terminal pleckstrin homology (PH) domain, 
a kinase domain, and a C-terminal regulatory domain containing a hydrophobic motif. Akt is 
normally kept in an inactive form through the intramolecular interaction between the PH and 
kinase domains. Binding of Akt to PIP3 at the membrane induces a conformational change in Akt 
that enables PDK1 to phosphorylate Akt at the Thr308 site of the activation loop. Maximal Akt 
activity is achieved when the Ser473 site in the hydrophobic motif is phosphorylated by mTOR 
complex 2 (mTORC2). Activated Akt dissociates from the cell membrane and can phosphorylate 
a wide range of molecular targets involved in many different cellular process including 
metabolism, translation, proliferation, survival, and angiogenesis (Wiza et al. 2012). The serine 
1177 site of eNOS is one target substrate of active Akt. Phosphorylated Akt (p-Akt) has been 
shown to be increased in female hearts during reperfusion and is believed to play an important 
role in sex-dependent cardioprotection (Bae and Zhang 2005; Shao et al. 2017b).  
 
Figure 3. Estrogen - PI3K/Akt signaling pathway. 
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1.4.4 Clinical therapy  
 
Our laboratory and others have identified intrinsic cardioprotective signaling mechanisms that 
serve to reduce cardiac injury in animal models of ischemia reperfusion-injury. Despite these 
advancements in cardiovascular research there has yet to be a cardioprotective therapy that has 
successfully reduced infarct size in humans, aside from reperfusion. While age and comorbidities 
are expected to partially underlie the failures of these clinical trials, environmental factors are 
expected to play a major role. Common exposures to environmental pollutants such as metals and 
fine particulate matter may abrogate the intrinsic cardioprotective signaling mechanisms, placing 
exposed populations at a heightened risk to develop cardiovascular disease. Arsenic is one 
common drinking water pollutant that is expected to contribute to the development of 
cardiovascular disease through the disruption of cardioprotective signaling mechanisms.  
 
1.5 Arsenic toxicity 
 
The toxic metalloid is a major water contaminant in the Western and Midwestern United States, 
and regions around the globe, including Chile, Bangladesh, India, and Taiwan. (Smith et al. 
2000). Inorganic arsenic is a carcinogen and is toxic to most organ systems in the human body 
because it effects a variety of enzyme catalyzed biological reactions and cell signaling pathways 




1.5.1 Arsenic within the environmental health paradigm 
  
Figure 4. The environmental health paradigm.  
 
1.5.1.1 Arsenic speciation, sources, and distribution 
 
Arsenic is a naturally occurring metalloid element found in the soil, air, and water. The presence 
of arsenic in the environment has resulted from both natural and anthropogenic sources. The 
metalloid is a constituent of over 200 minerals. The element exists primarily in arsenates, 
sulfides, and sulfosalts, though it also exists in arsenides, arsenites, oxides, silicates, and as 
elemental arsenic (Garelick et al. 2008b). Arsenic can be integrated into a carbon and hydrogen 
structure in which it is referred to as organic arsenic. Arsenic can exist in an inorganic state, 
where the metalloid is combined with elements like oxygen and sulfur. In the inorganic form, 
arsenic exists in two different valence states that differ in composition and chemical reactivity. 
Arsenic in the trivalent state (As3+) is referred to as arsenite and in the pentavalent state (As5+) is 
referred to as arsenate. Arsenite and arsenate primarily exist in a complex with other elements 
including sodium, sulfur, and oxygen (Alamolhodaei et al. 2015). The toxicity of arsenic is 
mainly attributed to the inorganic species with trivalent arsenic being the most toxic. The 
mechanisms of toxicity are expected to differ between the two species of inorganic arsenic (Stea 
et al. 2014). Arsenic has become extensively mobilized as a result of industrial process. 
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Anthropogenic activities driving an increase in environmental arsenic concentrations includes the 
use of pesticides, the use of wood preservatives, the combustion of fossil fuels, mining, smelting, 
and the discharge of mining and ore processing waste. Mining and smelting serve as the most 
significant contributors to the environmental arsenic contamination. Arsenic is found in ores 
containing uranium, lead, gold, zinc, nickel, and cobalt. The mining operations generate tailings, 
residual waste rock from the mined ore, which contains a variety of arsenic compounds. The 
arsenic mineral forms regularly found on mining sites and of particular concern are arsenopyrite, 
arsenian, pyrite, realgar, and orpiment. The predominance of the different mineral forms and the 
mobility of the arsenic species is dependent on the soil type as well as the pH and redox potential 
of the soil. Closed mining sites lacking restoration programs leave behind tailings and waste 
materials that release arsenic into the environment as a result of natural weathering processes 
(Larios et al. 2012). Elevated concentrations of environmental arsenic can also result from 
burning arsenic rich coals. Coal burning for cooking and heating purposes results in arsenic 
contaminated consumer food products. Arsenic has been introduced into the environment as a 
result of extensive pesticide applications for agricultural activities. In addition to the usage of 
arsenic compounds as pesticides, chromated arsenicals have been used as wood preservatives 
within the timber industry (Garelick et al. 2008b).  
 
1.5.1.2 Routes of exposure  
 
Human exposure to arsenic occurs primarily through environmental and occupational sources 
(Alamolhodaei et al. 2015). Arsenic exposure can occur through inhalation, ingestion, or 
cutaneous absorption. Ingestion of drinking water serves as the greatest source of exposure to 
inorganic arsenic as the arsenic found in water is almost entirely inorganic. Due to the insolubility 
of elemental arsenic in water, the inorganic arsenic found in drinking water is in the form of 
arsenite and arsenate (Stea et al. 2014). Occupational exposures to arsenic are common in 
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chemical manufacturing, electronic manufacturing, and pesticide use and manufacturing workers. 
Humans can also become exposed to arsenic through medical treatments for disease states 
including psoriasis and acute promyeloctic leukemia (Alamolhodaei et al. 2015).  
 
1.5.1.3 Individual and population health effects overview  
 
Arsenic is a fascinating element as it has been considered to be both a poison and a medicine 
throughout history depending on the time and context. Arsenic’s ability to induce apoptosis has 
allowed the metalloid to serve as a treatment of several diseases. Arsenic has been shown to 
induce complete remission in patients with acute promyeloctic leukemia, a cancer of the white 
blood cells (Soignet et al. 1998). While arsenic has been utilized as a medicine, the metalloid is 
primarily known as a driver of disease. Epidemiological studies have linked chronic and acute 
exposure to arsenic with a wide variety of disease states. Exposure to high doses of soluble 
inorganic arsenic may result in gastrointestinal, cardiopulmonary, cardiovascular, and central 
nervous system disorders. Intravenous infusion of trivalent arsenic for the treatment of 
promyeloctic leukemia has resulted in cases of sudden death. Human exposures to inorganic 
arsenic at fatally high doses present clinically with profound cardiac dysfunction, including QT 
prolongation, T-wave changes, ST segment depression, multifocal ventricular tachycardia and 
myocarditis (Alamolhodaei et al. 2015). Chronic arsenic exposure is believed to cause cancer, 
bronchopulmonary, cardiovascular, and metabolic diseases and neuropathies. Exposures to 
arsenic results in skin lesions and keratosis, the growth of keratin on the skin resulting in large 
and often benign skin growths (States et al. 2011). Chronic effects of arsenic on the cardiac 
system includes hypertension and the pathogenesis of atherosclerosis, peripheral vascular disease, 
and cardiomyopathy (Navas-Acien et al. 2005a). Due to the wide range of potential disease states 




1.5.2 Population based evidence of arsenic and cardiovascular disease  
 
Epidemiological studies in areas of the world with high levels of arsenic in ground water have 
found associations with exposure to inorganic arsenic with risks of development of multiple 
forms of cardiovascular disease, including hypertension, carotid atherosclerosis, ischemic heart 
disease, and vascular disease mortality (Chen et al. 1995; Chen et al. 1996; Chen et al. 2007; 
Hsieh et al. 2011; Hsueh et al. 1998; Wang et al. 2002). Arsenic exposure through the ingestion 
of contaminated drinking water is a serious problem in the Asian nations of Taiwan, Bengal, and 
Bangladesh as a result of the naturally high geological arsenic concentrations. The situation in 
Bangladesh is being referred to as one of the largest mass poisonings of a population in history 
with the nation’s drinking water being contaminated with inorganic arsenic concentrations up to 
2500 ppb. It is estimated that 37 to 77 million people in the Bangladesh population are at risk of 
drinking the contaminated water (Smith et al. 2000). Epidemiological studies in Bangladesh have 
found strong associations between arsenic exposures, reduced methylation capacity, and risks of 
development of fatal and non-fatal forms of cardiovascular disease (Chen et al. 2013). Arsenic is 
considered the probable cause of blackfoot disease, which is a severe form of peripheral arterial 
disease endemic to southwestern Taiwan. Epidemiological studies in Taiwan also support a 
strong association between arsenic exposure and atherosclerosis. In Antofagasta, Chile, 
histopathological studies of children and young adults exposed to high levels of arsenic found 
thickening of arterial walls and early signs of myocardial infarction (Navas-Acien et al. 2005a). 
The effects of chronic exposures to low and moderate levels of arsenic were largely unknown 
until publication of the Strong Heart Cohort study shed light on the issue in 2013. Water 
contamination from abandoned hard rock mine lands has created cohorts of Native American 
communities facing exposure to low and moderate concentrations of arsenic in drinking water 
within the United States. Arsenic is the most common metal contaminant of the most extensively 
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mined metals which includes gold, uranium, copper, and lead. It is estimated that roughly 
600,000 Native Americans live within 10 km of abandoned mine land (Lewis et al. 2017). The 
Strong Heart Study is the largest prospective cohort study in the United States to investigate the 
association between chronic exposure to low and moderate concentrations of inorganic arsenic 
and the incidence of cardiovascular disease. The study was conducted on three Native American 
communities in Arizona, Oklahoma, and North and South Dakota facing low to moderate 
concentration of arsenic exposure (<10 to 61 µg/L in Arizona, <10 µg/L in Oklahoma, and <1 to 
21 µg/L in the Dakotas). Using urine as a biomarker of exposure, Ana Navas-Acien’s group 
found low to moderate chronic arsenic exposure to be associated with both fatal and non-fatal 
forms of cardiovascular disease, including coronary heart disease (Moon et al. 2013). 
 
1.5.3 Arsenic metabolism  
 
Most of the inorganic arsenic ingested is excreted rapidly in the urine. A relatively small amount 
of arsenic is modified by methylation and redox reactions to generate methylarsonate (MMAV), 
methylarsonous acid (MMAIII), dimethylarsinic acid (DMAV), and dimethylarsinous acid 
(DMAIII). The trivalent arsenic metabolites are believed to be more potent toxins that the 
pentavalent species (Miller et al. 2002). Reduced methylation capabilities, as a result of genetic 
polymorphisms in methylation enzymes, are associated with a greater incidence of cardiovascular 
disease resulting from arsenic exposure (Chen et al. 2013). The process of arsenic methylation is 
referred to as biotransformation. The overall structure of the pathway and the enzymes involved 
in arsenic metabolism are still debated. The generally accepted pathway of biotransformation 
occurring in the liver consists of a series of reduction and oxidation reactions, coupled with 
methylations (Figure 5). In the traditional pathway, pentavalent arsenic is formed before the 
trivalent arsenic species. There are still many uncertainties in this pathway and alternative 
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pathways have been proposed. A commonly cited alternative pathway of arsenic 
biotransformation that has gained significant support was proposed by Hayakawa (Figure 6) 
(Aposhian and Aposhian 2006). 
 
 
Figure 5. Traditional pathway of arsenic biotransformation credited to Challenger, Cullen, and 
Reimer (Aposhian and Aposhian 2006).  
 
 
Figure 6. Alternative pathway of arsenic biotransformation proposed by Hayakawa (Aposhian 




1.5.4 Arsenic’s physiological modes of action  
 
1.5.4.1 Protein interactions 
 
Inorganic arsenic is considered a molecular analog of phosphate and can compete with phosphate 
in many biochemical reactions. By substituting for phosphate in oxidative phosphorylation, 
Inorganic arsenic inhibits ATP generation. Arsenite also has a high affinity for thiol groups and 
can bind to cysteine residues in proteins. Multiple studies have reported that arsenic exposure 
decreases GSH levels. Inorganic arsenic has also been shown to decrease the total accessible thiol 
content (Alamolhodaei et al. 2015). Inorganic arsenic binding to proteins can alter protein 
confirmation thereby disrupting protein functions and interactions with other proteins and DNA 
(Shen et al. 2013).  
 
1.5.4.2 Generation of ROS  
 
Arsenic trioxide is a known stimulator of ROS generation pathways (Han et al. 2010). Arsenic 
trioxide has been shown to induce the generation of intracellular ROS in a dose dependent 
manner (Chayapong et al. 2017). Arsenic also has been shown to increase the level of the 
oxidized from of GSH (GSSG) (Alamolhodaei et al. 2015). Cell cycle analysis of skin fibroblast 
cells treated with arsenic trioxide were observed to undergo cell cycle arrest, spending a 
significant amount of time in the G0/G1 phases with a reduction in the time spent in S phase. It is 
proposed that treatment with arsenic trioxide leads to oxidative stress, causing a shift in the cell 





1.5.4.3 Endocrine disruptor  
 
Arsenic is a known disruptor of endocrine function and reproductive fitness (Shalat et al. 1996). 
Arsenic exposure has been directly linked to a later menarche age in females of Bangladesh 
villages with naturally high levels of arsenic in drinking water (Sen and Chaudhuri 2007). In 
addition to menarche age, arsenic exposure in Bangladesh has had a significant correlation with 
birth defects (von Ehrenstein et al. 2006). These studies provide evidence for arsenic driven 
dysregulation of estrogen levels in the body and an altered state of the hypothalamic-pituitary-
gonadal axis, which plays a critical role in the development and regulation of many organ 
systems. It is proposed that arsenic disrupts endocrine and reproductive physiological function 
through the metalloids interaction with estrogen and estrogen signaling pathways. Arsenic has 
been shown to reduce plasma estrogen levels in a dose dependent manner (Chatterjee and 
Chatterji 2010a). It has been proposed that inorganic arsenic binds directly to 17b-estradiol and 
abolishes the effects of the hormone (Kumar et al. 2016). Arsenite has been considered an 
environmental estrogen as it has been shown to bind to the hormone binding site of ERa blocking 
the site from estradiol activation (Miller et al. 2002).  
 
1.6 Specific aims, objectives, and rationales  
 
1.6.1 Investigate the effect of inorganic arsenic exposure on cardiac structure 
 
The direct effects of arsenic exposure on cardiac structure is not fully understood. Arsenic 
exposure has been related to various cardiovascular diseases including hypertension. Long term 
hypertension and the associated increased afterload can lead to left ventricular hypertrophy which 
is indicated by an increase in left ventricular mass. Left ventricular hypertrophy is a strong 
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predictor of the cardiovascular and peripheral vascular complications, including ischemic heart 
disease, atherosclerosis, and stroke (Mehta et al. 2007; Verdecchia et al. 2007). Epidemiological 
studies have found a positive correlation between chronic arsenic exposure and cardiovascular 
diseases and risk factors including atherosclerosis, hypertension, diabetes, and peripheral arterial 
disease (Mazumder et al. 2012; Navas-Acien et al. 2005b; Newman et al. 2016; Rahman et al. 
1999; Tseng et al. 2006). Female mice exposed to water containing 100ppb of sodium arsenite for 
22 weeks were shown to exhibit increased systolic and diastolic blood pressure, indicating the 
manifestation of chronic hypertension. Echocardiographic analysis of the female mouse hearts 
was also indicative of concentric left ventricular hypertrophy (Sanchez-Soria et al. 2012a). We 
had reason to believe that 4 weeks of exposure to water containing sodium arsenite would lead to 
changes in the echocardiographic parameters indicating signs of left ventricular hypertrophy. We 
set out to determine if 4 weeks of arsenic exposure leads to cardiac remodeling in male and 
female mice using transthoracic echocardiography.  
 
1.6.2 Determine the effect of inorganic arsenic exposure on sex-dependent susceptibility to 
ischemia-reperfusion injury 
 
Consistent with previous animal studies, our group has observed greater post-ischemic functional 
recovery with female mouse hearts compared to males after 20 minutes of ischemia and 30 
minutes of reperfusion (Figure 7) (Shao et al. 2016). An abolishment of female cardioprotection 
is observed in ovariectomized mice (Ross and Howlett 2012). The female heart’s intrinsic 
resilience to ischemia-reperfusion injury is believed to be mitigated through estrogen signaling, as 
an abolishment of female cardioprotection is observed in ovariectomized mice (Ross and Howlett 
2012). Estrogen has been observed to drive rapid, short term cardioprotective effects in the heart 
through the activation of signaling pathways (Menazza and Murphy 2016; Wu et al. 2011). One 
such cardioprotective effect of particular importance is the upregulation of eNOS and NO 
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signaling. Using SNO resin assistant capture (SNO-RAC) in tandem with mass spectrometry, we 
have observed that female hearts exhibited 65% more unique SNO protein identifications 
compared with male hearts (Figure 8) (Shao et al. 2016). This is suggestive of a protective role of 
nitric oxide signaling in the female heart. Trivalent arsenic is believed to disrupt endocrine 
function through the metalloid’s interactions with estrogen signaling (Shalat et al. 1996).  Arsenic 
exposures are associated with birth defects and a delayed onset of menarche (Chatterjee and 
Chatterji 2010a; Kumar et al. 2016; Sen and Chaudhuri 2007; Shalat et al. 1996; von Ehrenstein 
et al. 2006). Trivalent arsenic exposure has been shown to reduce serum estradiol levels in a dose 
and time dependent manner in female albino rats (Chatterjee and Chatterji 2010b). It is proposed 
that trivalent arsenic abrogates estrogen signaling though the direct binding to 17b-estradiol 
(Kumar et al. 2016). We have reason to believe that arsenic may disrupt estrogen mediated sex-
dependent cardioprotection. Therefore, we set out to investigate the effects of inorganic arsenic 
exposure on sex-dependent cardioprotection using the Langendorff-perfused mouse heart model 
of ischemia-reperfusion injury with male and female hearts. We hypothesized that trivalent 
arsenic treatment would abrogate sex-dependent cardioprotection through the metalloid’s direct 
actions on 17b-estradiol.  
 
 
Figure 7. Female hearts exhibit greater post-ischemic functional recovery. Post-ischemic 
functional recovery in Langendorff-perfused male and female hearts following 20 min of 




Figure 8. Female hearts show enhanced baseline myocardial SNO levels. (A) Total S-nitrosothiol 
(SNO) protein and peptide identifications at baseline in male and female hearts identified via 
SNO-resin-assisted-capture (SNO-RAC). (B) Venn Diagram depicting common and unique SNO 
protein identification in male and female hearts (Shao et al. 2016).  
 
1.6.3 Investigate the effect of inorganic arsenic exposure on the PI3K/Akt signaling pathway 
 
Ser1177 of eNOS is a downstream phosphorylation target of PI3K activated p-Akt. 
Phosphorylation of eNOS at ser1117 leads to greater activity of eNOS and upregulation of NO 
signaling. Our group has observed increased expression and phosphorylation of eNOS at baseline 
in female hearts compared to males (Figure 9) (Shao et al. 2016; Shao et al. 2017a). Consistent 
with the increased expression and activation of eNOS observed in females, we have observed 
increased NOx (NO, nitrite, nitrate) levels at baseline in whole heart homogenates of female 
hearts compared to male hearts (Figure 10). The addition of L-NIO, a specific inhibitor for eNOS, 
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led to a significant reduction in NOx production. However, selective nNOS inhibition with SMLT 
had no effect on the NOx  levels, suggesting that eNOS expression and activation was responsible 
for the NOx production. (Moon et al. 2013). Estrogen treatment has been shown to cause 
phosphorylation of Ser1177 and activation of eNOS in the heart through the PI3K/Akt pathway 
(Guo et al. 2006; Hisamoto et al. 2001). Vascular endothelial cells treated with sodium arsenite 
showed decreased protein levels of Akt1 and eNOS. The upregulation of eNOS was shown to 
attenuate the effects of the arsenite exposure (Tsou et al. 2005). An epidemiological study of an 
Inner Mongolia population chronically exposed to inorganic arsenic through drinking water were 
observed to have reduced serum concentrations of NO metabolites (Pi et al. 2000). We have 
reason to believe that trivalent arsenic is acting on Akt, eNOS, or on an upstream regulator like 
estrogen, causing a reduced activity of eNOS and reduced NO levels. We set out to investigate 
the effects of trivalent arsenic exposure on the PI3K/Akt pathway with a focus on eNOS activity 




Figure 9. eNOS expression and phosphorylation is increased in female hearts. (A) Baseline eNOS 
expression and (B) phosphorylation at Ser1177 in male and female hearts as assessed via western 





Figure 10. Baseline NOx production is increased in female hearts. Baseline NOx production 
assessed in male and female hearts via a colorimetric assay with SMLT serving as a selective 
inhibitor of NNOS and L-NIO as non-selective inhibitor of NOS. #p=0.075 vs. male +NAPDH -
SMLT –LNIO, *p<0.05 vs. male +NAPDH -SMLT –LNIO, **p<0.05 vs female +NAPDH -
SMLT –LNIO (Shao et al. 2016). 
 
1.6.4 Overall study goal, hypothesis, and significance  
 
The overall goal of the study is to characterize the effects of inorganic arsenic exposure on 
susceptibility to ischemia-reperfusion injury. Additionally, this project aims to identify the 
specific mechanisms through which inorganic arsenic exposure alters susceptibility to ischemia 
reperfusion injury. We hypothesized that iAS would inhibit estrogen signaling and receptor 
mediated gene expression thereby disrupting sex-dependent cardioprotection. The results of this 
study will provide valuable insights into the vast epidemiological evidence illustrating the 
positive correlation between arsenic exposure and ischemic heart disease. Identifying the 
mechanistic basis of inorganic arsenic cardiotoxicity may lead to better biomarkers of toxicity 
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and treatment options for chronic arsenic toxicity. We hope that our results highlight the 
immediate need for better arsenic contamination prevention and remediation plans. We will 
continue to work to establish firm mechanistic connections between environmental agents and 






Inorganic Arsenic Exposure and Susceptibility to Ischemic Heart Injury 
 
2.1 Introduction  
 
Heart disease is the leading cause of morbidity and mortality, both in the United States and 
throughout the developed world (Benjamin et al. 2017; Roth et al. 2017). Epidemiological studies 
suggest that the majority of cardiovascular disease is preventable, highlighting the 
environmentally driven nature of the disease (Willett 2002). Compared to age-matched men, pre-
menopausal women have historically had a reduced risk of cardiovascular disease. This sex-
dependent phenomenon declines with menopause, suggesting a role for estrogen in the protection 
(Hayward et al. 2000). Females have been shown to exhibit endogenous cardioprotective 
signaling mechanisms derived from the beneficial effects of estradiol (Murphy et al. 2011; Shao 
et al. 2016). Several animal studies have shown estrogen and the activation of the estrogen 
receptors to be cardioprotective during ischemia-reperfusion injury (Booth et al. 2005; Hale et al. 
1996; Lagranha et al. 2010; Lin et al. 2009a; M Wang et al. 2006). It is well established that 
females have a lower incidence of ischemic heart disease, left ventricle hypertrophy, and cardiac 
remodeling after an acute myocardial infarction. This is verified in preclinical animal studies in 
which females exhibit improved functional recovery and smaller infarct sizes following ischemia-
reperfusion (I/R) (Bae and Zhang 2005; Shao et al. 2017a). Surprisingly, the divide between male 
and female ischemic heart disease mortality rates is narrowing according to the American Heart 
Association. Age-adjusted mortality after a myocardial infarction declined among males, but not 
females between 2001 to 2003 and 2007 to 2009 (Benjamin et al. 2017). 
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Numerous studies provide associations between heart disease and exposures to environmental 
pollutants, including particulate matter, gases, and metals (Cosselman et al. 2015). However, the 
exact mechanism(s) by which these pollutants drive heart disease have yet to be fully elucidated. 
These exposures may be differentially affecting males and females, effectively narrowing the gap 
in ischemic heart disease mortality rates. One pollutant directly linked to heart disease in 
epidemiological studies is the naturally occurring metalloid, inorganic arsenic (iAS). iAs toxicity 
is a global health problem, affecting millions of people lacking access to contaminant free 
drinking water. Chronic exposure to iAS has been linked to the manifestation of a vast array of 
disease states, including cancer (Lin et al. 2013; Smith et al. 2006), type 2 diabetes (Navas-Acien 
et al. 2008), neurological and cognitive defects (Wasserman et al. 2004), reproductive and 
developmental issues (Myers et al. 2010; Sen and Chaudhuri 2007; von Ehrenstein et al. 2006), 
and various cardiovascular diseases including atherosclerosis (Engel and Smith 1994; Huang et 
al. 2009), hypertension (Huang et al. 2007), and ischemic heart disease (Hsueh et al. 1998; 
Navas-Acien et al. 2005a; Tseng et al. 2003). The World Health Organization recommends that 
municipal water concentrations of iAS not exceed 10ppb. Despite this recommendation, the toxic 
metalloid remains at elevated levels and as a major water contaminant in the Western and 
Midwestern United States and regions around the globe including Chile, Bangladesh, India, and 
Taiwan (Nordstrom 2002). Elevated levels of iAS in water sources have resulted from the 
extensive mobilization of the species due to both natural and industrial processes including 
mining, agriculture, and fuel combustion (Garelick et al. 2008a; Larios et al. 2012). Relatively 
high ground water levels of iAS are found in Bangladesh, Taiwan, India, and Chile with 
populations exposed to water concentrations up to 2500 ppb (Nordstrom 2002). iAS water 
contamination is by no means restricted to developing regions of the world. A century of mining 
in the United States and the subsequent abandonment of mine lands has left Native American 
communities utilizing private drinking water wells exposed to toxic levels of iAS. The Strong 
Heart Study has illuminated the association between chronic exposure to low levels of iAS and 
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the incidence of both fatal and non-fatal forms of cardiovascular disease in Native American 
communities of Arizona, Oklahoma, and North and South Dakota (Moon et al. 2013). 
Epidemiological studies link iAS exposure with risks of developing peripheral vascular disease, 
hypertension, carotid atherosclerosis, cardiomyopathy, and ischemic heart disease (Chen et al. 
1995; Chen et al. 1996; Chen et al. 2007; Hsieh et al. 2011; Hsueh et al. 1998; Wang et al. 2002). 
iAS is believed to drive hypertension by promoting oxidative stress, lipid peroxidation, and loss 
of vasodilators in endothelial cells and smooth muscle cells (Ellinsworth 2015). Pressure overload 
due to hypertension is considered the major risk factor for the development of hypertrophic 
cardiomyopathy (Burchfield et al. 2013). The ability for iAs to induce cardiac remodeling either 
directly or indirectly by promoting peripheral vascular stress is still debated. Female mice 
exposed to 100 ppb iAS for 22 weeks were shown to have an increased left ventricular mass, 
interventricular septal wall thickness, blood pressure, and relative wall thickness illustrating some 
characteristics of concentric left ventricular hypertrophy (Sanchez-Soria et al. 2012b). Mouse 
models of atherosclerosis confirm that moderate iAs exposure enhances atherosclerotic plaque 
formation with less stable lesions through the promotion of pro-inflammatory conditions 
(Lemaire et al. 2011). Additionally, animal studies and In-vitro studies have shown that iAS 
exposure can disrupt cardiomyocyte calcium homeostasis, alter mitochondrial permeability, and 
cause cardiomyocyte apoptosis (Chen et al. 2010; Larochette et al. 1999; Raghu and Cherian 
2009; Zhao et al. 2008). 
 
The relationship between iAS exposure and ischemic heart disease is poorly understood, and 
mechanistic studies are lacking. Therefore, we set out to examine the effects of iAS exposure on 
susceptibility to ischemic heart injury using an ex vivo mouse model of injury in both males and 
females. Epidemiological studies provide a clear link between iAS exposure and ischemic heart 
disease. In addition to driving cardiovascular disease, iAS is considered an endocrine disruptor, 
altering sex steroid signaling and receptor mediated gene expression (Chatterjee and Chatterji 
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2010a; Davey et al. 2007; Watson and Yager 2007). Although female hearts exhibit an estrogen-
dependent reduction in susceptibility to ischemic injury compared to males, females may be 
especially susceptible to iAS due to the endocrine disrupting effects. Nitric oxide signaling is at 
the root of estrogen-mediated cardioprotection. Our group and others have previously identified 
that female hearts exhibit higher nitric oxide levels and more unique S-nitrosylated peptides 
compared with male hearts (Shao et al. 2016). Endothelial nitric oxide synthase (eNOS) 
expression, phosphorylation, and activation is regulated by estrogen signaling and estrogen 
receptor mediated gene regulation (Deschamps et al. 2010; Marino et al. 2006). We have 
previously shown that female mice have higher levels of eNOS, and more activated eNOS 
compered to males (Shao et al. 2017a). Female albino rats exposed to 4000 ppb iAS were 
observed to have significantly diminished circulating estradiol, luteinizing hormone (LH), and 
follicle-stimulating hormone (FSH) levels (Chatterjee and Chatterji 2010a). It has been proposed 
that iAS binds directly to 17b-estradiol and abolishes the effects of the hormone (Kumar et al. 
2016). Our results suggest that an environmental exposure such as iAS, can modulate 
susceptibility to ischemic heart disease. Our results further suggest that iAs can modulate 
myocardial nitric oxide signaling to either increase or decrease susceptibility to ischemic injury. It 
remains unclear if this result is mediated through changes in circulating estradiol. Future studies 
will aim to develop the connection between iAs endocrine disrupting effects, myocardial nitric 
oxide signaling, and alterations in susceptibility to ischemic heart injury. We hypothesize that 
iAS exposure alters the nitroso-redox equilibrium thereby differentially modulating susceptibility 







2.2 Materials and methods  
 
2.2.1 Animals and iAS exposure protocol  
 
Seven week old Male and female C57BL/6J mice were purchased from Jackson Laboratory (Bar, 
Harbor, ME). A total of 140 mice were used in this study. The mice were housed in a vivarium 
facility at Johns Hopkins University under specific pathogen-free conditions in rooms that 
maintain a constant temperature, humidity, and a 14-hour light/8-hour dark cycle. The animals 
were provided water and chow ad libitum. Each individual cage was provided with HEPA filtered 
air and bedding that was changed 2-3 times per week. The mice were provided Research Diet Inc. 
AIN-93G diet (Research Diet) and Nestle Pure Life water certified to contain no detectable level 
of iAS. The mice were acclimated to the feed, water, and housing conditions for one week prior 
to conducting the sodium arsenite exposure protocol. All mice utilized for the study were sexually 
mature at the age of eight weeks. The mice were given Nestle Pure Life drinking water containing 
0 ppb (control), 10 ppb, 100 ppb, or 1000 ppb of iAS in the form of sodium arsenite (Sigma-
Aldrich) for a total of four weeks of exposure. Water containing sodium arsenite were refreshed 
every 2-3 days to minimize oxidation. For all procedures, mice were anesthetized with a mixture 
of ketamine (Hofspira, Inc., Lake Forest, IL; 90 mg/kg) and xylazine (Sigma, St. Louis, MO; 10 
mg/kg). After verifying adequate anesthesia via toe pinch, mice were subsequently euthanized via 
myocardial excision and exsanguination. This investigation conforms to the Guide for the Care 
and Use of Laboratory Animals published by the United States National Institutes of Health (NIH 
publication NO. 85-23, revised 2011) and was approved by the Institutional Animal Care and Use 





2.2.2 Assessment of cardiac remodeling with transthoracic echocardiography  
 
Transthoracic echocardiography was performed in conscious mice using a Vevo 2100 system 
with a 40-MHz mechanical transducer (FUJIFILM VisualSonics, Toronto, Canada). The M-mode 
echocardiogram was acquired from the parasternal short axis view of the left ventricle (LV) at the 
level of the mid-papillary muscles and at a sweep speed of 200 mm/sec. From this axis view of 
the left ventricle, the following cardiac parameters were measured, including inter-ventricular 
septal thickness at end diastole (IVSD), LV chamber diameter at end diastole (LVEDD), posterior 
wall thickness at end diastole (PWTED), and LV chamber diameter at end systole (LVESD). 
Using these parameters, the percent fractional shortening (FS %), relative wall thickness (RWT), 
and left ventricle mass (LV mass) were used in the estimation of cardiac contractility and left 
ventricle morphology. These indices were derived from the following equations: 
 
FS (%) = [(LVEDD – LVESD)/LVEDD] x 100 
EF (%) = [(LVEDD2-LVESD2)/LVEDD2] x 100 
LV mass (mg): 1.055 [IVSD + LVEDD + PWTED)3 – (LVEDD)3], where 1.055 is the specific 
gravity of the myocardium 
RWT = (PWTED/LVEDD) x 2 
 
The end-diastolic and end-systolic ventricular volumes (EDV, ESV), stroke volume (SV), and the 
percent ejection fraction (EF) were estimated using the Simpson’s method and the two chamber 






2.2.3 Determination of susceptibility to ischemia-reperfusion injury 
 
2.2.3.1 Langendorff perfused heart model 
 
The isolated perfused heat model, developed by Oscar Langendorff in 1897, was used to simulate 
ischemia-reperfusion injury. Despite its development over 100 years ago, the Langendorff-
perfused heart model remains as the standard tool for investigating cardiac injury. The model has 
served invaluable in cardiac research allowing for the development of an understanding of basic 
heart physiology such as myocardial infarction, electrophysiology, coronary vascular function, 
and clinically presenting cardiac disease states (Bell et al. 2011). With the development of more 
advanced genomics, proteomics, and metabolomics techniques, the Langendorff-perfused heart 
model has allowed for the investigation of complex myocardial physiology and cellular signaling 
pathways. Limitations of the isolated heart model includes the absences of normal hormonal and 
neuronal regulation of cardiac function. Additionally, the model is characterized by high coronary 
flow and edema as the perfusate generally lacks a cellular component. The isolation of the heart 
from confounding peripheral influences can serve as a strength of the model as it allows for a 
better understanding of the direct actions of toxins and pharmaceuticals (Skrzypiec-Spring et al. 
2007). The ex-vivo approach allows for the isolation of multiple experimental variables that can 
influence contractile function including temperature, oxygen, and calcium ion concentrations of 
the perfusate. Anoxia and hypoxia can easily be imposed on the heart providing a valuable tool of 
simulating both local and global ischemia (Skrzypiec-Spring et al. 2007). The Langendorff heart 
model utilizes a retrograde perfusion trough the aorta with fluid flow that is opposite to the 
normal physiological flow. Due to the retrograde flow of the perfusate the leaflets of the aortic 
arch close and the fluid enters the coronary arteries directly via the ostia at the aortic root. 
Through the ostia and the right and left branching coronary arteries, the ventricular mass is 
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perfused and the fluid empties into the right atria through the coronary sinus (Sutherland and 
Hearse 2000).  
 
2.2.3.2 Krebs-Henseleit perfusate 
 
Krebs-Henseleit buffer (KHB) was used as the perfusate in the Langendorff-perfused heart assay. 
This is the most common bicarbonate buffer utilized by researchers investing cardiac pathology 
with a Langendorff-perfused heart model (Bell et al. 2011). The KHB solute concentrations were 
set at 120 mmol/L NaCl, 4.7 mmol/L KCL, 1.2 mmol/L KH2PO4, 25 mmol/L NaHCO3, 1.2 
mmol/L MgSO4, 11 mmol/L D-glucose, 1.75 mmol/L CaCl2. To mimic physiological conditions, 
the pH of the KHB was set to 7.4 and the temperature was maintained at 37 °C. 
 
2.2.3.3 Ischemia-reperfusion protocol, myocardial infarct staining, and functional recovery 
analysis 
 
After conducting the post exposure transthoracic echocardiography measurements, the mice were 
subjected to the ex-vivo Langendorff-perfused heart assay. Mice were anesthetized with a 
mixture of ketamine and xylazine via an intraperitoneal injection. Heparin was then administered 
as an anticoagulant. Hearts were excised from the male and female mice and placed directly in 
ice-cold Krebs-Henseleit buffer. The aorta of the heart was cannulated and perfused in a 
retrograde fashion in the dark at a constant pressure of 100 cm of buffer with the KHB at pH 7.4 
and a temperature of 37 °C. For both the control and the treatment groups, the hearts were 
subjected to a standard ischemia-reperfusion protocol of 20 minutes of equilibration, 20 minutes 
of ischemia, and 120 minutes of reperfusion (Figure 11). A latex balloon connected to a pressure 
transducer was inserted into the left ventricle to measure left ventricular developed pressure 
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(LVDP) and heart rate. Both left ventricular developed pressure and heart rate were monitored 
and recorded using the PowerLab system. The rate pressure product was used as a measure of 
cardiac contractile function. 
 
Figure 11. Ischemia-reperfusion protocol. 
 
After the completion of the ischemia-reperfusion protocol, hearts were perfused with Triphenyl 
tetrazolium chloride (TTC) and fixed in formalin. Triphenyl tetrazolium chloride was used as a 
gross histochemical staining technique to facilitate the rapid identification of the myocardial 
infarction at the macroscopic level. The Triphenyl tetrazolium chloride interacts with intact 
dehydrogenase enzymes to form a red precipitate. Necrotic tissue lacks the presence of active 
dehydrogenases and therefore fails to form a red precipitate (Fishbein et al. 1981). White 
Infarcted tissue can easily be distinguished from the viable tissue stained red. In addition to 
assessing myocardial infarct size, functional recovery as determined following the completion of 
the ischemia-reperfusion protocol. The post-ischemic functional recovery will be determined by 
assessing left ventricular developed pressure and heart rate during the myocardial perfusion to be 
able to calculate the rate pressure product for measurement of cardiac contractile function. The 







2.2.4 Liver alanine transaminase activity 
 
Alanine transaminase (ALT) activity was assessed in whole liver homogenates from male and 
female mice, previously exposed to 0 ppb iAS (control) or 1000 ppb iAS for four weeks via 
drinking water, using a commercially available kit (Abcam). Approximately 15 mg of liver tissue 
was homogenized in 200ul of assay buffer for each sample using a Dounce glass homogenizer on 
ice and centrifuged at 14,000 g for 10 minutes at 4 oC to pellet debris. The supernatant was 
recovered as total crude homogenate. Sample protein concentration was determined using the 
Bradford protein assay. Exactly 5 µl of sample was added to 15 µl of assay buffer in an individual 
well of a 96-well plate. To initiate the reaction, 100ul of a mixture containing the ALT substrates 
alanine and a-ketoglutarate, ALT enzyme cofactors, and an oxired probe was added to each 
individual well. ALT catalyzes the transfer of an amino group from alanine to a-ketoglutarate to 
produce pyruvate and glutamate. Pyruvate then converts the colorless probe to a color with a 570 
nm wavelength. Pyruvate production was thereby indirectly monitored via absorbance at 570 nm 
wavelength for 10 minutes at 37oC. ALT activity was calculated from pyruvate produced between 
reaction time 2 minutes and 10 minutes using the equation below.  
 
ALT activity = ((B/DT*V)*DF)/[S] 
 
DT = reaction time   
B = nmol pyruvate produced over DT 
V = volume of sample added 
DF = sample dilution factor  
[S] = sample protein concentration  
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ALT activity was expressed in terms of Units where 1 Unit (U) of ALT is the amount of ALT 
which generates 1.0 µmol of pyruvate per minute at 37 oC. Samples were ran in duplicate and 
average ALT activity was determined.  
 
2.2.5 Plasma 17b-estradiol levels 
 
Blood was extracted from the inferior vena cava and collected in tubes treated with heparin. Cells 
were removed by centrifugation at 14,000 g for 10 minutes at 4°C. Supernatant was collected and 
stored at -80°C. Plasma samples were analyzed for 17b-estradiol concentrations at the UVA 
Center for Research in Reproduction Ligand Assay and Analysis Core using a commercially 
available estradiol Elisa kit (Calbiotech Inc) per the manufacturers instruction.  
 
2.2.6 Whole heart homogenate preparation 
 
A separate set of mice were given Nestle Pure Life drinking water containing 0ppb (control) or 
1000ppb of iAS in the form of sodium arsenite for a total of four weeks of exposure. Hearts were 
excised and Langendorff perfused for 20 minutes in the dark. Following perfusion, hearts were 
snap frozen in liquid nitrogen. All subsequent procedure were completed in the dark. Hearts were 
powdered on liquid nitrogen with a mortar and pestle, and resuspended in 1.0 mL of 
homogenization buffer containing (in mmol/L): sucrose (300), HEPES-NaOH pH 8.0 (250), 
EDTA (1), neocuproine (0.1), and Triton-X 100 (0.5%). An EDTA-free protease inhibitor tablet 
(Roche, Indianapolis, IN) was added just before use. Samples were then homogenized using a 
Dounce glass homogenizer on ice and centrifuged at 14,000 g for 30 minutes to pellet debris. The 
supernatant was recovered as total crude homogenate. 
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Protein concentration was determined using the Bradford protein assay. Total homogenates were 
then aliquoted and stored at -80oC. 
 
2.2.7 Western blots for eNOS, p-eNOS, Akt, p-Akt, nNOS, and iNOS 
 
Samples were separated on a 4-12% Bis-Tris SDS-PAGE gel and transferred to a nitrocellulose 
membrane (Life Technologies). Membranes were blocked with 5% (w/v) nonfat dried 
milk in Tris-buffered saline with 0.1% Tween-20 for one hour, and subsequently incubated 
with primary antibodies against phospho-Akt Ser473 (1:1000, Cell Signaling Technology, 
Danvers, MA, 4060S), total Akt (1:1000, Cell Signaling Technologies, 4691S), phospho-eNOS 
Ser1177 (1:500; Cell Signaling Technology, 9570s), total eNOS (1:250; Santa Cruz 
Biotechnology, Dallas, TX), nNOS (1:250, Santa Cruz Biotechnology, Dallas, TX), or iNOS 
(1:250, Santa Cruz Biotechnology, Dallas, TX). Membranes were then probed with the 
corresponding secondary antibodies for 1 hour and visualized by electrogenerated 
chemiluminescence (Life Technologies). Densitometry was assessed using ImageJ software 
(National Institutes of Health, Bethesda, MD). 
 
2.2.8 Statistics  
 
Results are expressed as the mean±SEM. Statistical significance (p<0.05) was determined 
between groups using a Student's t-test for two groups or a two-way ANOVA with Tukey's 






2.3 Results  
 
2.3.1 iAS has sex disparate effects on susceptibility to ischemic heart injury 
 
To determine the effect of iAS exposure on sex-dependent susceptibility to ischemic heart injury, 
we subjected male and female mouse hearts, previously exposed to 0 ppb (control), 10 ppb , 100 
ppb, or 1000 ppb for four weeks, to a standard I/R protocol of 20 mins of equilibration, 20 mins 
of ischemia, and 120 mins of reperfusion, and assessed recovery of function and myocardial 
infarct size. In mice exposed to 10ppb or 100ppb of iAs, we detected no significant changes in 
susceptibility to I/R injury in both male and female groups; post-ischemic functional recovery and 
infarct size was not significantly different compared to non-iAS exposed mice. Following 
1000ppb iAS exposure, however, we identified substantial sex-dependent changes in I/R 
susceptibility. iAS-treated female hearts showed a significant decrease in post-ischemic 
functional recovery and increased infarct size, while iAS-treated males showed significantly 
enhanced post-ischemic functional recovery and reduced infarct size (Figure 12). 
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Figure 12. Four weeks of exposure to 1000 ppb iAS results in sex disparate effects on 
susceptibility to ischemic heart injury. After four weeks of exposure to 0 ppb (control) or 1000 
ppb iAS via drinking water, hearts were excised and Langendorff-perfused. For all treatment 
groups, hearts were equilibrated for 20 mins, subjected to 20 mins of ischemia, and reperfused for 
120 mins. (A-B) Post-ischemic functional recovery at 90 mins of reperfusion. (C-D) Post-I/R 
myocardial infarct size. Hearts were perfused with 10% Triphenyl tetrazolium chloride (TTC) 
and fixed in formalin following reperfusion. ImageJ software was used to analyze infarct size, 
expressed as the percentage of total area of cross-sectional slices. Numbers inside each bar 





2.3.2 No difference in weight change, feed consumption, or water intake is observed with iAS 
exposure  
 
Since dietary restriction and dehydration modulates susceptibility to ischemia-reperfusion injury 
(Mitchell et al. 2010), we monitored feed and water intake during the acclimation to housing 
conditions and throughout the duration of the exposure. Feed and water consumption was 
recorded when replaced every 2-3 days. Mouse weight was measured once a week. We observed 
no significant difference between treatment groups in feed consumption or water intake during 
acclimation to the housing conditions or during the exposure (Figure 13). Additionally, we did 
not observe a significant difference in overall weight change or rate of weight change during the 









Figure 13. No difference in feed consumption or water intake is observed with iAS exposure. (A-
C) Feed consumption during exposure protocol for all three iAS doses (n= 5 per group). (D-F) 





Figure 14. No difference in overall weight change or rate of weight change is observed with iAS 
exposure. (A-C) Overall weight change expressed as the difference between the post-exposure 
weight and the pre-exposure weight (n = 10 per group). (D-F) Mouse weight recorded weekly 
during the duration of the iAS exposure (n = 5 per group).  
 
2.3.3 Moderate iAS exposure induces modest cardiac remodeling with no change in gross cardiac 
function in females 
 
iAS exposure is associated with major risk factors for pathological cardiac hypertrophy, including 
hypertension, atherosclerosis, and type two diabetes. Since pathological cardiac hypertrophy 
increases susceptibility to ischemic heart injury (Penna et al. 2011), we assessed the cardiac 
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geometry and function of both male and female hearts, pre- and post-exposure, for all three iAS 
doses using transthoracic echocardiography. We did not observe significant changes in cardiac 
geometry or function with exposure to the 10 ppb or 100 ppb iAS doses in male or female mice 
(data not shown). We did observe a modest but significant increase in IVSd and LV mass in 1000 
ppb iAS-treated females (vs. non-treated females) (Table 1). Despite observing a significant 
increase in IVSd and LV mass, we did not observe changes in myocardial function (i.e., ejection 
fraction, fractional shortening, heart rate, etc.) that would signify cardiac dysfunction and/or 
pathological cardiac hypertrophy.  
 
Table 1. Echocardiographic parameters for pre- and post-1000 ppb iAS exposure. 
Echo  
Parameter 
Male Control Male 1000 ppb 
iAS exposure 
Female Control Female 1000 ppb 
iAS exposure 
Pre Post Pre Post Pre Post Pre Post 

































































































































































































* p<0.05 vs. post-exposure female control (n = 4 - 5 per group) 
 
HR: heart rate; EF: ejection fraction; FS: fractional shortening; EDV: end-diastolic ventricular volume; ESV: end-systolic ventricular 
volume; SV: stroke volume; IVSd: interventricular septal thickness at end diastole; LVIDd: left ventricular internal diameter at end 
diastole; LVIDs: left ventricular internal diameter at end systole; LVPWd: left ventricular posterior wall at end diastole; RWT: relative 
wall thickness; LV Mass: left ventricle mass. 
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2.3.4 Liver toxicity was not observed with iAS exposure 
 
The remaining experiments were conducted on control mice and mice exposed to 1000 ppb iAS 
as we observed cardiac phenotypic changes only at this concentration in our four week exposure 
model. To investigate if the change in susceptibility to ischemic injury was a result of toxicity to 
other organ systems, we examined the liver, which is a major target of both arsenic toxicity and 
arsenic carcinogenesis. Noncirrhotic fibrosis is common in individuals chronically exposed to a 
high dose of iAS. ALT activity reflects damage to hepatocytes and is considered a specific and 
highly sensitive biomarker of hepatotoxicity (Aubrecht et al. 2013). Evaluation of ALT activity 
revealed no signs of toxicity in either male or female mice treated with 1000 ppb iAs (Figure 15).  
 
 
Figure 15. Liver toxicity is not observed in mouse iAS exposure model in male or female mice 
according to ALT activity, an established clinical biomarker of liver toxicity. ALT activity was 
assessed in whole liver homogenates of male and female mice previously exposed to 0 ppb 
(control) or 1000 ppb iAS for four weeks. ALT activity was expressed in terms of Units where 1 
Unit (U) of ALT is the amount of ALT which generates 1.0 µmol of pyruvate per minute at 37ºC. 
(n = 10 per group). 
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2.3.5 iAS exposure reduces circulating 17β-estradiol levels in females 
 
Since female hearts normally exhibit an estrogen-dependent reduction in susceptibility to 
ischemic injury and we have observed significantly greater susceptibility to I/R injury with iAS 
exposure, we examined the plasma 17b-estradiol levels of 1000 ppb iAS-treated male and female 
mice. We observed a decrease in 17b-estradiol levels in iAS-treated females (vs. non-treated 




Figure 16. iAS exposure reduces circulating 17β-estradiol levels in females, but this decrease is 
not significant. 17β-estradiol levels were assessed by ELISA in plasma samples of male and 
female mice previously exposed to 0 ppb (control) or 1000 ppb iAS for four weeks. Numbers 
inside each bar represent the number of mice used for each group. 
 
2.3.6 iAS alters myocardial nitric oxide signaling independent of PI3K/Akt signaling pathway 
 
NO signaling appears to be a key component of sex-dependent cardioprotection, and we have 
shown that female hearts exhibit increased expression and phosphorylation of eNOS, as well as 
enhanced phospho-Akt levels, at baseline compared to males (Shao et al. 2016; Shao et al. 
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2017a). Therefore, we next examined Akt and eNOS as potential targets of iAS exposure. eNOS 
protein levels were significantly decreased in whole heart homogenates from both iAS-treated 
male and female hearts (Figure 17G-H). eNOS phosphorylation at Ser1177 was also significantly 
elevated in iAs-treated male hearts and remained unchanged in iAS-treated female hearts (Figure 
17E-F). No change was observed in either Akt or phospho-Akt levels in iAs-treated male or 







Figure 17. iAS alters myocardial nitric oxide signaling independent of PI3K/Akt signaling 
pathway. (A-B) Western blot depicting phosphorylated (Ser473) Akt levels in control and 1000 
ppb iAS-treated male and female hearts. (C-D) Western blot depicting Akt levels in control and 
1000 ppb iAS-treated male and female hearts. (E-F) Western blot depicting phosphorylated 
(Ser1177) eNOS levels in control and 1000 ppb iAS-treated male and female hearts. (G-H) 
Western blot depicting eNOS levels in control and 1000 ppb iAS-treated male and female hearts 




2.3.7 iAS does not alter nNOS or iNOS expression in the heart 
 
To further investigate the effect of iAS exposure on NO signaling, we probed for the other two 
other isoforms of NOS, nNOS and iNOS. We observed no significant change in nNOS protein 
levels (Figure 18A-B), and iNOS expression was not detected in either male or female hearts 
(Figure 18C). Macrophage cell lysate was used as a positive control for iNOS.  
 
 
Figure 18. iAS does not alter nNOS or iNOS expression in the heart. (A-B) Western blot 
depicting nNOS levels in control and 1000 ppb iAS-treated male and female hearts. (C) Western 
blot depicting iNOS levels in control and 1000 ppb iAS-treated male and female hearts. 
Macrophage cell lysate (MCL) was used as a positive control for iNOS (n = 5 per group).  
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2.4 Discussion  
 
Numerous epidemiological studies link iAS exposure to an increased risk of ischemic heart 
disease. Despite the clear epidemiological link to ischemic heart disease, the mechanism(s) by 
which arsenic alters susceptibility to ischemic heart injury is unclear. We hypothesized that 
females are especially susceptible to ischemic injury with iAS exposure due to endocrine 
disrupting effects. We have demonstrated for the first time in an animal model that iAS exposure 
alters susceptibility to ischemic heart injury. We identified substantial sex-dependent changes in 
I/R susceptibility following only four weeks of 1000 ppb iAs exposure. As hypothesized, iAS-
treated female hearts exhibited significantly more injury following I/R with a significant decrease 
in post-ischemic functional recovery and increased infarct size. Surprisingly, a four week 1000 
ppb iAS treatment appears to protect the male heart against ischemic heart injury. iAS-treated 
male hearts showed significantly enhanced post-ischemic functional recovery and reduced infarct 
size following I/R. 
 
After establishing the sex disparate effect of iAS exposure on susceptibility to ischemic heart 
injury, we proceeded to investigate the underlying mechanistic basis. First, we considered the link 
between iAS exposure and peripheral vascular diseases, including atherosclerosis and 
hypertension, that may cause pathological cardiac hypertrophy and place the heart at a greater 
susceptibility to I/R injury. An epidemiological study of children in Mexico has linked early life 
iAS exposure to elevated blood pressure, higher LV mass, and reduced EF (Osorio-Yanez et al. 
2015). Transthoracic echocardiography revealed only modest changes in cardiac geometry with a 
significantly increased IVSd and LV mass in only 1000 ppb iAS-treated female mice. These 
results are consistent with a previous study that identified an increase in IVSd and LV mass in 
addition to a significant increase in RWT in female mice exposed to 100 ppb iAS for 22 weeks 
(Sanchez-Soria et al. 2012b). Despite the modest changes in cardiac geometry, we did not 
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observe any changes in function that would place the heart at a greater susceptibility to ischemic 
heart injury.  
 
With pathological cardiac hypertrophy excluded as a culprit for the altered susceptibility to 
ischemic heart injury, we considered toxicity to other organ systems as a potential mechanism. 
We examined toxicity of the liver, a major target of both arsenic toxicity and arsenic 
carcinogenesis, using liver ALT activity as a biomarker of hepatocyte damage. Elevated ALT 
activity has been reported in mouse models exposed to 3200 ppb iAS for 12 months and 4900 ppb 
iAS for 10 months (Santra et al. 2000; Tan et al. 2011). Consistent with pervious animal studies 
utilizing similar arsenic exposure models in rats and C57BL/6J mice (Arteel et al. 2008; Lemaire 
et al. 2011), we did not observe altered ALT liver enzyme activity in either male or female mice 
treated with 1000 ppb iAS for four weeks (Figure 15). 
 
Next, we hypothesized that iAS decreased circulating 17b-estradiol levels in females, thereby 
disrupting estrogen signaling and receptor mediated gene expression, leading to a greater 
susceptibility to I/R injury. iAS has been shown to reduce estrogen levels in a dose dependent 
manner as well as disrupt estrogen signaling and receptor mediated gene expression in vitro and 
in female albino rats (Chatterjee and Chatterji 2010a; Davey et al. 2007; Watson and Yager 
2007). We observed reduced circulating 17b-estradiol levels in iAS-treated females (vs. non-
treated females), but this was not statistically significant. Additionally, 17b-estradiol levels were 
unexpectedly low across all treatment groups and we did not detect a difference between male 
and female mice. More sensitive and specific methodology will need to be developed to examine 
17b-estradiol levels in mouse models. Nonetheless, we have previously shown eNOS and Akt to 
be involved in sex-dependent cardioprotection so we proceeded to examine those targets. We 
have shown that eNOS protein levels are significantly decreased in whole heart homogenates 
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from both iAS-treated male and female hearts. We have also shown that eNOS phosphorylation 
(Ser1177) levels are significantly elevated in iAs-treated male hearts and unchanged in iAs-
treated females. This increase in activation of eNOS may be driving the protection observed in 
iAS-treated males. Additionally, we have shown that the other two NOS isoforms, iNOS and 
nNOS, remain unchanged with iAS exposure. Altogether, our results suggests that iAS exposure 
differentially effects NO signaling in male and female hearts thereby driving sex-dependent 
changes in susceptibility to ischemic heart injury.  
 
In summary, we have shown that an environmental exposure can modulate susceptibility to 
ischemic heart injury. We demonstrated that iAS exposure has sex-dependent effects on 
susceptibility to ischemic heart injury. Our results suggest that environmentally relevant 
concentrations of iAS may be of much greater health risk to women.  
 
2.5 Future directions  
 
Future studies will aim to further illuminate the mechanism(s) underlying the altered 
susceptibility to ischemic injury observed in male and female hearts exposed to 1000 ppb iAS for 
four weeks. Our results suggest that iAS exposure differentially effects NO signaling in male and 
female hearts thereby driving sex-dependent changes in susceptibility to ischemic heart injury. 
Therefore, a main focus of future studies will be on the effect of iAS exposure on myocardial 
nitric oxide signaling and the nitroso-redox equilibrium.  
 
We have identified significantly reduced eNOS levels in both iAS-treated male and female hearts. 
We will determine if the decreased eNOS protein levels is a result of changes in gene regulation, 
an issue of translation, or a result of increased eNOS degradation. We will use quantitative PCR 
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to examine the relative eNOS mRNA expression in male and female hearts exposed to 0 ppb 
(control) and 1000 ppb iAS for four weeks.  
 
We have also identified significantly elevated phosphorylated (Ser1177) eNOS levels in iAS-
treated male hearts despite observing no change in PI3K/Akt signaling. The Ca2+/calmodulin-
dependent protein kinase (CaMKII) has previously been shown to phosphorylate Ser1177 of 
eNOS (Fleming et al. 2001). CaMKII activity is regulated by cytoplasmic calcium levels and 
previous in-vitro studies have shown that iAS can increase intracellular calcium levels (Florea et 
al. 2005). iAS may be increasing phosphorylated (Ser1177) eNOS levels either by increasing 
CaMKII expression or by increasing CaMKII activity by increasing intracellular calcium levels. 
We will examine CaMKII phosphorylation and expression by western blot.  
 
While we have identified significant and differential changes in eNOS expression and activation 
in iAS-treated male and female hearts, we cannot conclude that NO signaling is enhanced in male 
hearts and reduced in female hearts. We will examine NOx (nitrite, nitrate) levels in iAS-treated 
male and female hearts to understand how NO levels correlate with eNOS expression and 
activation. We will then examine the effect of iAS exposure on NO signaling in male and female 
hearts by looking at SNO peptide levels using the SNO resin assistant capture (SNO-RAC) in 
tandem with mass spectrometry.  
 
In addition to investigating changes in NO signaling, we will look at ROS levels in male and 
female hearts previously exposed to 0 ppb (control) and 1000 ppb iAS for four weeks. iAS has 
been shown to stimulate ROS generation pathways and oxidative stress (Han et al. 2010). We will 
examine hydrogen peroxide levels post-iAS exposure in male and female hearts using the 
Amplex Red Hydrogen Peroxide Assay kit.  
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We have observed modest but significant changes in gross cardiac structure with no change in 
cardiac function in female mice exposed to 1000 ppb iAS for four weeks. We believe that with 
prolonged iAS exposure, female mice will exhibit pathological hypertrophy with changes in 
cardiac function in addition to structure. We also expect to see change in male cardiac structure 
with prolonged exposure to iAS. A future study will examine gross cardiac structure and function 
changes in male and female mouse hearts following treatment with 0 ppb (control), 10 ppb, 100 
ppb, and 1000 ppb iAS for different durations of exposure (16, 24 , 32 wks). We will also monitor 
tail blood pressure periodically throughout the IAS exposure protocol to determine if changes in 
cardiac structure and function have resulted from hypertension. We will continue to examine 
changes in susceptibility to ischemic injury using the Langendorff perfused heart assay as we 
expect that we will observe changes in susceptibility at much lower concentrations of iAS with 
longer exposure times. Additionally, we expect that males will exhibit greater susceptibility to 
ischemic heart injury at more prolonged exposure times. We believe that any protective signaling 
in males that was upregulated with the brief iAS exposure will become pathological or 















Ahuja P, Sdek P, MaClellan WR. 2007. Cardiac myocyte cell cycle control in development, 
disease, and regeneration. Physiological Reviews 87:521-544. 
Aktan F. 2004. Inos-mediated nitric oxide production and its regulation. Life Sci 75:639-653. 
Alamolhodaei NS, Shirani K, Karimi G. 2015. Arsenic cardiotoxicity: An overview. Environ 
Toxicol Pharmacol 40:1005-1014. 
Alderton WK, Cooper CE, Knowles RG. 2001. Nitric oxide synthases: Structure, function and 
inhibition. Biochem J 357:593-615. 
Andrew PJ, Mayer B. 1999. Enzymatic function of nitric oxide synthases. Cardiovasc Res 
43:521-531. 
Aposhian HV, Aposhian MM. 2006. Arsenic toxicology: Five questions. Chem Res Toxicol 19:1-
15. 
Arteel GE, Guo L, Schlierf T, Beier JI, Kaiser JP, Chen TS, et al. 2008. Subhepatotoxic exposure 
to arsenic enhances lipopolysaccharide-induced liver injury in mice. Toxicol Appl Pharmacol 
226:128-139. 
Aubrecht J, Schomaker SJ, Amacher DE. 2013. Emerging hepatotoxicity biomarkers and their 
potential to improve understanding and management of drug-induced liver injury. Genome Med 
5:85. 
Bae S, Zhang L. 2005. Gender differences in cardioprotection against ischemia/reperfusion injury 
in adult rat hearts: Focus on akt and protein kinase c signaling. J Pharmacol Exp Ther 315:1125-
1135. 
Baines CP. 2009. The mitochondrial permeability transition pore and ischemia-reperfusion injury. 
Basic Res Cardiol 104:181-188. 
Bairey Merz CN, Johnson BD, Sharaf BL, Bittner V, Berga SL, Braunstein GD, et al. 2003. 
Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: 
A report from the nhlbi-sponsored wise study. J Am Coll Cardiol 41:413-419. 
Barouch LA, Harrison RW, Skaf MW, Rosas GO, Cappola TP, Kobeissi ZA, et al. 2002. Nitric 
oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 
416:337-340. 
Barry WH, Bridge JHB. 1993. Intracellular calcium homeostasis in cardiac myocytes. Circulation 
87:1806-1815. 
Becker LB. 2004. New concepts in reactive oxygen species and cardiovascular reperfusion 
physiology. Cardiovasc Res 61:461-470. 
Bell RM, Mocanu MM, Yellon DM. 2011. Retrograde heart perfusion: The langendorff technique 
of isolated heart perfusion. J Mol Cell Cardiol 50:940-950. 
 70 
Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. 2017. Heart disease and 
stroke statistics-2017 update: A report from the american heart association. Circulation 135:e146-
e603. 
Bhatnagar D, Anand IS, Durrington PN, Patel DJ, Wander GS, Mackness MI, et al. 1995. 
Coronary risk-factors in people from the indian subcontinent living in west london and their 
siblings in india. Lancet 345:405-409. 
Booth EA, Obeid NR, Lucchesi BR. 2005. Activation of estrogen receptor-alpha protects the in 
vivo rabbit heart from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 289:H2039-
2047. 
Burchfield JS, Xie M, Hill JA. 2013. Pathological ventricular remodeling: Mechanisms: Part 1 of 
2. Circulation 128:388-400. 
Capurso C, Massaro M, Scoditti E, Vendemiale G, Capurso A. 2014. Vascular effects of the 
mediterranean diet part i: Anti-hypertensive and anti-thrombotic effects. Vasc Pharmacol 63:118-
126. 
Chatterjee A, Chatterji U. 2010a. Arsenic abrogates the estrogen-signaling pathway in the rat 
uterus. Reprod Biol Endocrinol 8:80. 
Chatterjee A, Chatterji U. 2010b. Arsenic abrogates the estrogen-signaling pathway in the rat 
uterus. Reprod Biol Endocrin 8. 
Chayapong J, Madhyastha H, Madhyastha R, Nurrahmah QI, Nakajima Y, Choijookhuu N, et al. 
2017. Arsenic trioxide induces ros activity and DNA damage, leading to g0/g1 extension in skin 
fibroblasts through the atm-atr-associated chk pathway. Environ Sci Pollut Res Int 24:5316-5325. 
Chen CJ, Hsueh YM, Lai MS, Shyu MP, Chen SY, Wu MM, et al. 1995. Increased prevalence of 
hypertension and long-term arsenic exposure. Hypertension 25:53-60. 
Chen CJ, Chiou HY, Chiang MH, Lin LJ, Tai TY. 1996. Dose-response relationship between 
ischemic heart disease mortality and long-term arsenic exposure. Arterioscler Thromb Vasc Biol 
16:504-510. 
Chen X, Shan H, Zhao J, Hong Y, Bai Y, Sun I, et al. 2010. L-type calcium current (ica,l) and 
inward rectifier potassium current (ik1) are involved in qt prolongation induced by arsenic 
trioxide in rat. Cell Physiol Biochem 26:967-974. 
Chen Y, Factor-Litvak P, Howe GR, Graziano JH, Brandt-Rauf P, Parvez F, et al. 2007. Arsenic 
exposure from drinking water, dietary intakes of b vitamins and folate, and risk of high blood 
pressure in bangladesh: A population-based, cross-sectional study. Am J Epidemiol 165:541-552. 
Chen Y, Wu F, Liu M, Parvez F, Slavkovich V, Eunus M, et al. 2013. A prospective study of 
arsenic exposure, arsenic methylation capacity, and risk of cardiovascular disease in bangladesh. 
Environ Health Perspect 121:832-838. 
Cooper CE. 1999. Nitric oxide and iron proteins. Bba-Bioenergetics 1411:290-309. 
 71 
Cosselman KE, Navas-Acien A, Kaufman JD. 2015. Environmental factors in cardiovascular 
disease. Nat Rev Cardiol 12:627-642. 
Cross HR, Murphy E, Steenbergen C. 2002. Ca(2+) loading and adrenergic stimulation reveal 
male/female differences in susceptibility to ischemia-reperfusion injury. Am J Physiol Heart Circ 
Physiol 283:H481-489. 
Davey JC, Bodwell JE, Gosse JA, Hamilton JW. 2007. Arsenic as an endocrine disruptor: Effects 
of arsenic on estrogen receptor-mediated gene expression in vivo and in cell culture. Toxicol Sci 
98:75-86. 
Deschamps AM, Murphy E, Sun J. 2010. Estrogen receptor activation and cardioprotection in 
ischemia reperfusion injury. Trends Cardiovasc Med 20:73-78. 
Ellinsworth DC. 2015. Arsenic, reactive oxygen, and endothelial dysfunction. J Pharmacol Exp 
Ther 353:458-464. 
Engel RR, Smith AH. 1994. Arsenic in drinking water and mortality from vascular disease: An 
ecologic analysis in 30 counties in the united states. Arch Environ Health 49:418-427. 
Fishbein MC, Meerbaum S, Rit J, Lando U, Kanmatsuse K, Mercier JC, et al. 1981. Early phase 
acute myocardial infarct size quantification: Validation of the triphenyl tetrazolium chloride 
tissue enzyme staining technique. Am Heart J 101:593-600. 
Fleming I, Fisslthaler B, Dimmeler S, Kemp BE, Busse R. 2001. Phosphorylation of thr(495) 
regulates ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res 
88:E68-75. 
Florea AM, Yamoah EN, Dopp E. 2005. Intracellular calcium disturbances induced by arsenic 
and its methylated derivatives in relation to genomic damage and apoptosis induction. Environ 
Health Perspect 113:659-664. 
Forstermann U, Sessa WC. 2012. Nitric oxide synthases: Regulation and function. Eur Heart J 
33:829-837, 837a-837d. 
Foster MW, Yang Z, Gooden DM, Thompson JW, Ball CH, Turner ME, et al. 2012. Proteomic 
characterization of the cellular response to nitrosative stress mediated by s-nitrosoglutathione 
reductase inhibition. J Proteome Res 11:2480-2491. 
Frey N, Olson EN. 2003. Cardiac hypertrophy: The good, the bad, and the ugly. Annu Rev 
Physiol 65:45-79. 
Garelick H, Jones H, Dybowska A, Valsami-Jones E. 2008a. Arsenic pollution sources. Rev 
Environ Contam Toxicol 197:17-60. 
Garelick H, Jones H, Dybowska A, Valsami-Jones E. 2008b. Arsenic pollution sources. Rev 
Environ Contam T 197:17-60. 
Grundtvig M, Hagen TP, German M, Reikvam A. 2009. Sex-based differences in premature first 
myocardial infarction caused by smoking: Twice as many years lost by women as by men. 
European Journal of Preventive Cardiology 16:174-179. 
 72 
Guo RX, Wei LH, Tu Z, Sun PM, Wang JL, Zhao D, et al. 2006. 17 beta-estradiol activates 
pi3k/akt signaling pathway by estrogen receptor (er)-dependent and er-independent mechanisms 
in endometrial cancer cells. J Steroid Biochem Mol Biol 99:9-18. 
Haas E, Meyer MR, Schurr U, Bhattacharya I, Minotti R, Nguyen HH, et al. 2007. Differential 
effects of 17beta-estradiol on function and expression of estrogen receptor alpha, estrogen 
receptor beta, and gpr30 in arteries and veins of patients with atherosclerosis. Hypertension 
49:1358-1363. 
Hale SL, Birnbaum Y, Kloner RA. 1996. Beta-estradiol, but not alpha-estradiol, reduced 
myocardial necrosis in rabbits after ischemia and reperfusion. Am Heart J 132:258-262. 
Han YH, Moon HJ, You BR, Kim SZ, Kim SH, Park WH. 2010. Effects of arsenic trioxide on 
cell death, reactive oxygen species and glutathione levels in different cell types. Int J Mol Med 
25:121-128. 
Hayward CS, Kelly RP, Collins P. 2000. The roles of gender, the menopause and hormone 
replacement on cardiovascular function. Cardiovasc Res 46:28-49. 
Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, et al. 2007. Estrogen 
receptors: How do they signal and what are their targets. Physiol Rev 87:905-931. 
Heusch G. 2015. Molecular basis of cardioprotection: Signal transduction in ischemic pre-, post-, 
and remote conditioning. Circ Res 116:674-699. 
Hisamoto K, Ohmichi M, Kurachi H, Hayakawa J, Kanda Y, Nishio Y, et al. 2001. Estrogen 
induces the akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial 
cells. J Biol Chem 276:3459-3467. 
Hsieh YC, Lien LM, Chung WT, Hsieh FI, Hsieh PF, Wu MM, et al. 2011. Significantly 
increased risk of carotid atherosclerosis with arsenic exposure and polymorphisms in arsenic 
metabolism genes. Environ Res 111:804-810. 
Hsueh YM, Wu WL, Huang YL, Chiou HY, Tseng CH, Chen CJ. 1998. Low serum carotene 
level and increased risk of ischemic heart disease related to long-term arsenic exposure. 
Atherosclerosis 141:249-257. 
Huang YK, Tseng CH, Huang YL, Yang MH, Chen CJ, Hsueh YM. 2007. Arsenic methylation 
capability and hypertension risk in subjects living in arseniasis-hyperendemic areas in 
southwestern taiwan. Toxicol Appl Pharmacol 218:135-142. 
Huang YL, Hsueh YM, Huang YK, Yip PK, Yang MH, Chen CJ. 2009. Urinary arsenic 
methylation capability and carotid atherosclerosis risk in subjects living in arsenicosis-
hyperendemic areas in southwestern taiwan. Sci Total Environ 407:2608-2614. 
Huxley AF, Niedergerke R. 1954. Structural changes in muscle during contraction; interference 
microscopy of living muscle fibres. Nature 173:971-973. 
Huxley H, Hanson J. 1954. Changes in the cross-striations of muscle during contraction and 
stretch and their structural interpretation. Nature 173:973-976. 
 73 
Johnson MS, Moore RL, Brown DA. 2006. Sex differences in myocardial infarct size are 
abolished by sarcolemmal katp channel blockade in rat. Am J Physiol Heart Circ Physiol 
290:H2644-2647. 
Joung B, Ogawa M, Lin SF, Chen PS. 2009. The calcium and voltage clocks in sinoatrial node 
automaticity. Korean Circ J 39:217-222. 
Kim JS, He LH, Lemasters JJ. 2003. Mitochondrial permeability transition: A common pathway 
to necrosis and apoptosis. Biochem Bioph Res Co 304:463-470. 
Kohr MJ, Aponte AM, Sun J, Wang G, Murphy E, Gucek M, et al. 2011a. Characterization of 
potential s-nitrosylation sites in the myocardium. Am J Physiol Heart Circ Physiol 300:H1327-
1335. 
Kohr MJ, Sun J, Aponte A, Wang G, Gucek M, Murphy E, et al. 2011b. Simultaneous 
measurement of protein oxidation and s-nitrosylation during preconditioning and 
ischemia/reperfusion injury with resin-assisted capture. Circ Res 108:418-426. 
Kohr MJ, Aponte A, Sun J, Gucek M, Steenbergen C, Murphy E. 2012. Measurement of s-
nitrosylation occupancy in the myocardium with cysteine-reactive tandem mass tags: Short 
communication. Circ Res 111:1308-1312. 
Kohr MJ, Evangelista AM, Ferlito M, Steenbergen C, Murphy E. 2014. S-nitrosylation of trim72 
at cysteine 144 is critical for protection against oxidation-induced protein degradation and cell 
death. J Mol Cell Cardiol 69:67-74. 
Kumar S, Mukherjee TK, Guptasarma P. 2016. Arsenic and 17-beta-estradiol bind to each other 
and neutralize each other's signaling effects. Biochem Bioph Res Co 477:575-580. 
Lagranha CJ, Deschamps A, Aponte A, Steenbergen C, Murphy E. 2010. Sex differences in the 
phosphorylation of mitochondrial proteins result in reduced production of reactive oxygen species 
and cardioprotection in females. Circ Res 106:1681-1691. 
Larios R, Fernandez-Martinez R, Alvarez R, Rucandio I. 2012. Arsenic pollution and 
fractionation in sediments and mine waste samples from different mine sites. Sci Total Environ 
431:426-435. 
Larochette N, Decaudin D, Jacotot E, Brenner C, Marzo I, Susin SA, et al. 1999. Arsenite induces 
apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp Cell Res 
249:413-421. 
LeBlanc AJ, Reyes R, Kang LS, Dailey RA, Stallone JN, Moningka NC, et al. 2009. Estrogen 
replacement restores flow-induced vasodilation in coronary arterioles of aged and ovariectomized 
rats. Am J Physiol Regul Integr Comp Physiol 297:R1713-1723. 
Lemaire M, Lemarie CA, Molina MF, Schiffrin EL, Lehoux S, Mann KK. 2011. Exposure to 
moderate arsenic concentrations increases atherosclerosis in apoe-/- mouse model. Toxicol Sci 
122:211-221. 
Levi F, Lucchini F, Negri E, La Vecchia C. 2002. Trends in mortality from cardiovascular and 
cerebrovascular diseases in europe and other areas of the world. Heart 88:119-124. 
 74 
Lewis J, Hoover J, MacKenzie D. 2017. Mining and environmental health disparities in native 
american communities. Curr Environ Health Rep 4:130-141. 
Li Y, Sirenko S, Riordon DR, Yang D, Spurgeon H, Lakatta EG, et al. 2016. Camkii-dependent 
phosphorylation regulates basal cardiac pacemaker function via modulation of local ca2+ 
releases. Am J Physiol Heart Circ Physiol 311:H532-544. 
Lin HJ, Sung TI, Chen CY, Guo HR. 2013. Arsenic levels in drinking water and mortality of liver 
cancer in taiwan. J Hazard Mater 262:1132-1138. 
Lin J, Steenbergen C, Murphy E, Sun J. 2009a. Estrogen receptor-beta activation results in s-
nitrosylation of proteins involved in cardioprotection. Circulation 120:245-254. 
Lin J, Steenbergen C, Murphy E, Sun JH. 2009b. Estrogen receptor-beta activation results in s-
nitrosylation of proteins involved in cardioprotection. Circulation 120:245-U157. 
Liu L, Yan Y, Zeng M, Zhang J, Hanes MA, Ahearn G, et al. 2004. Essential roles of s-
nitrosothiols in vascular homeostasis and endotoxic shock. Cell 116:617-628. 
Lochner A, Marais E, Genade S, Moolman JA. 2000. Nitric oxide: A trigger for classic 
preconditioning? Am J Physiol Heart Circ Physiol 279:H2752-2765. 
Lundberg JO, Weitzberg E, Gladwin MT. 2008. The nitrate-nitrite-nitric oxide pathway in 
physiology and therapeutics. Nat Rev Drug Discov 7:156-167. 
Maas AH, Appelman YE. 2010. Gender differences in coronary heart disease. Neth Heart J 
18:598-602. 
Marino M, Galluzzo P, Ascenzi P. 2006. Estrogen signaling multiple pathways to impact gene 
transcription. Curr Genomics 7:497-508. 
Martinez-Ruiz A, Lamas S. 2007. Signalling by no-induced protein s-nitrosylation and s-
glutathionylation: Convergences and divergences. Cardiovasc Res 75:220-228. 
Mazumder DG, Purkayastha I, Ghose A, Mistry G, Saha C, Nandy AK, et al. 2012. Hypertension 
in chronic arsenic exposure: A case control study in west bengal. J Environ Sci Heal A 47:1514-
1520. 
Mehta SK, Rame JE, Khera A, Murphy SA, Canham RM, Peshock RM, et al. 2007. Left 
ventricular hypertrophy, subclinical atherosclerosis, and inflammation. Hypertension 49:1385-
1391. 
Menazza S, Murphy E. 2016. The expanding complexity of estrogen receptor signaling in the 
cardiovascular system. Circ Res 118:994-1007. 
Mihl C, Dassen WR, Kuipers H. 2008. Cardiac remodelling: Concentric versus eccentric 
hypertrophy in strength and endurance athletes. Neth Heart J 16:129-133. 
Miller WH, Jr., Schipper HM, Lee JS, Singer J, Waxman S. 2002. Mechanisms of action of 
arsenic trioxide. Cancer Res 62:3893-3903. 
Mingos DMP. 2014. Historical introduction to nitrosyl complexes. Struct Bond 153:1-44. 
 75 
Mitchell JR, Verweij M, Brand K, van de Ven M, Goemaere N, van den Engel S, et al. 2010. 
Short-term dietary restriction and fasting precondition against ischemia reperfusion injury in 
mice. Aging Cell 9:40-53. 
Moon KA, Guallar E, Umans JG, Devereux RB, Best LG, Francesconi KA, et al. 2013. 
Association between exposure to low to moderate arsenic levels and incident cardiovascular 
disease. A prospective cohort study. Ann Intern Med 159:649-659. 
Moreira JD, Pernomian L, Gomes MS, Moreira RP, do Prado AF, da Silva CHTP, et al. 2016. 
Enhanced nitric oxide generation from nitric oxide synthases as the cause of increased 
peroxynitrite formation during acute restraint stress: Effects on carotid responsiveness to 
angiotensinergic stimuli in type-1 diabetic rats. European Journal of Pharmacology 783:11-22. 
Murphy E, Lagranha C, Deschamps A, Kohr M, Nguyen T, Wong R, et al. 2011. Mechanism of 
cardioprotection: What can we learn from females? Pediatr Cardiol 32:354-359. 
Murphy MP. 2016. Understanding and preventing mitochondrial oxidative damage. Biochem Soc 
T 44:1219-1226. 
Myers SL, Lobdell DT, Liu Z, Xia Y, Ren H, Li Y, et al. 2010. Maternal drinking water arsenic 
exposure and perinatal outcomes in inner mongolia, china. J Epidemiol Community Health 
64:325-329. 
Nabeebaccuus A, Shah AM. 2014. Biochemistry and physiology of cardiac muscle Medicine 
42:413-417. 
Navas-Acien A, Sharrett AR, Silbergeld EK, Schwartz BS, Nachman KE, Burke TA, et al. 2005a. 
Arsenic exposure and cardiovascular disease: A systematic review of the epidemiologic evidence. 
Am J Epidemiol 162:1037-1049. 
Navas-Acien A, Sharrett AR, Silbergeld EK, Schwartz BS, Nachman KE, Burke TA, et al. 2005b. 
Arsenic exposure and cardiovascular disease: A systematic review of the epidemiologic evidence. 
American Journal of Epidemiology 162:1037-1049. 
Navas-Acien A, Silbergeld EK, Pastor-Barriuso R, Guallar E. 2008. Arsenic exposure and 
prevalence of type 2 diabetes in us adults. JAMA 300:814-822. 
Newman JD, Navas-Acien A, Kuo CC, Guallar E, Howard BV, Fabsitz RR, et al. 2016. 
Peripheral arterial disease and its association with arsenic exposure and metabolism in the strong 
heart study. American Journal of Epidemiology 184:806-817. 
Nikolic I, Liu DX, Bell JA, Collins J, Steenbergen C, Murphy E. 2007. Treatment with an 
estrogen receptor-beta-selective agonist is cardioprotective. J Mol Cell Cardiol 42:769-780. 
Nordstrom DK. 2002. Public health. Worldwide occurrences of arsenic in ground water. Science 
296:2143-2145. 
Nuedling S, Karas RH, Mendelsohn ME, Katzenellenbogen JA, Katzenellenbogen BS, Meyer R, 
et al. 2001. Activation of estrogen receptor beta is a prerequisite for estrogen-dependent 
upregulation of nitric oxide synthases in neonatal rat cardiac myocytes. Febs Lett 502:103-108. 
 76 
O'Toole TE, Conklin DJ, Bhatnagar A. 2008. Environmental risk factors for heart disease. Rev 
Environ Health 23:167-202. 
Ong SB, Samangouei P, Kalkhoran SB, Hausenloy DJ. 2015. The mitochondrial permeability 
transition pore and its role in myocardial ischemia reperfusion injury. J Mol Cell Cardiol 78:23-
34. 
Osorio-Yanez C, Ayllon-Vergara JC, Arreola-Mendoza L, Aguilar-Madrid G, Hernandez-
Castellanos E, Sanchez-Pena LC, et al. 2015. Blood pressure, left ventricular geometry, and 
systolic function in children exposed to inorganic arsenic. Environ Health Perspect 123:629-635. 
Pacher P, Nivorozhkin A, Szabo C. 2006. Therapeutic effects of xanthine oxidase inhibitors: 
Renaissance half a century after the discovery of allopurinol. Pharmacol Rev 58:87-114. 
Parrish AB, Freel CD, Kornbluth S. 2013. Cellular mechanisms controlling caspase activation 
and function. Cold Spring Harb Perspect Biol 5. 
Patel JV, Vyas A, Cruickshank JK, Prabhakaran D, Hughes E, Reddy KS, et al. 2006. Impact of 
migration on coronary heart disease risk factors: Comparison of gujaratis in britain and their 
contemporaries in villages of origin in india. Atherosclerosis 185:297-306. 
Patten RD, Pourati I, Aronovitz MJ, Baur J, Celestin F, Chen X, et al. 2004. 17beta-estradiol 
reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 
kinase/akt signaling. Circ Res 95:692-699. 
Peluffo G, Radi R. 2007. Biochemistry of protein tyrosine nitration in cardiovascular pathology. 
Cardiovasc Res 75:291-302. 
Penna C, Tullio F, Perrelli MG, Moro F, Abbadessa G, Piccione F, et al. 2011. 
Ischemia/reperfusion injury is increased and cardioprotection by a postconditioning protocol is 
lost as cardiac hypertrophy develops in nandrolone treated rats. Basic Res Cardiol 106:409-420. 
Pi J, Kumagai Y, Sun G, Yamauchi H, Yoshida T, Iso H, et al. 2000. Decreased serum 
concentrations of nitric oxide metabolites among chinese in an endemic area of chronic arsenic 
poisoning in inner mongolia. Free Radic Biol Med 28:1137-1142. 
Powers SK, Murlasits Z, Wu M, Kavazis AN. 2007. Ischemia-reperfusion-induced cardiac injury: 
A brief review. Med Sci Sport Exer 39:1529-1536. 
Qian J, Fulton D. 2013. Post-translational regulation of endothelial nitric oxide synthase in 
vascular endothelium. Front Physiol 4. 
Raghu KG, Cherian OL. 2009. Characterization of cytotoxicity induced by arsenic trioxide (a 
potent anti-apl drug) in rat cardiac myocytes. J Trace Elem Med Biol 23:61-68. 
Rahman M, Tondel M, Ahmad SA, Chowdhury IA, Faruquee MH, Axelson O. 1999. 
Hypertension and arsenic exposure in bangladesh. Hypertension 33:74-78. 
Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. 2005. A transmembrane 
intracellular estrogen receptor mediates rapid cell signaling. Science 307:1625-1630. 
 77 
Ross JL, Howlett SE. 2012. Age and ovariectomy abolish beneficial effects of female sex on rat 
ventricular myocytes exposed to simulated ischemia and reperfusion. PLoS One 7:e38425. 
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. 2002. 
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results 
from the women's health initiative randomized controlled trial. JAMA 288:321-333. 
Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. 2017. Global, regional, 
and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol 
70:1-25. 
Sanchez-Soria P, Broka D, Monks SL, Camenisch TD. 2012a. Chronic low-level arsenite 
exposure through drinking water increases blood pressure and promotes concentric left 
ventricular hypertrophy in female mice. Toxicol Pathol 40:504-512. 
Sanchez-Soria P, Broka D, Monks SL, Camenisch TD. 2012b. Chronic low-level arsenite 
exposure through drinking water increases blood pressure and promotes concentric left 
ventricular hypertrophy in female mice. Toxicol Pathol 40:504-512. 
Santra A, Maiti A, Das S, Lahiri S, Charkaborty SK, Mazumder DN. 2000. Hepatic damage 
caused by chronic arsenic toxicity in experimental animals. J Toxicol Clin Toxicol 38:395-405. 
Schwartz Longacre L, Kloner RA, Arai AE, Baines CP, Bolli R, Braunwald E, et al. 2011. New 
horizons in cardioprotection: Recommendations from the 2010 national heart, lung, and blood 
institute workshop. Circulation 124:1172-1179. 
Segal AW. 2008. The function of the nadph oxidase of phagocytes and its relationship to other 
noxs in plants, invertebrates, and mammals. Int J Biochem Cell B 40:604-618. 
Sen J, Chaudhuri ABD. 2007. Effect of arsenic on the onset of menarcheal age. B Environ 
Contam Tox 79:293-296. 
Senyo SE, Lee RT, Kuhn B. 2014. Cardiac regeneration based on mechanisms of cardiomyocyte 
proliferation and differentiation. Stem Cell Res 13:532-541. 
Shalat SL, Walker DB, Finnell RH. 1996. Role of arsenic as a reproductive toxin with particular 
attention to neural tube defects. J Toxicol Environ Health 48:253-272. 
Shao Q, Fallica J, Casin KM, Murphy E, Steenbergen C, Kohr MJ. 2016. Characterization of the 
sex-dependent myocardial s-nitrosothiol proteome. Am J Physiol Heart Circ Physiol 310:H505-
515. 
Shao Q, Casin KM, Mackowski N, Murphy E, Steenbergen C, Kohr MJ. 2017a. Adenosine a1 
receptor activation increases myocardial protein s-nitrosothiols and elicits protection from 
ischemia-reperfusion injury in male and female hearts. PLoS One 12:e0177315. 
Shao Q, Casin KM, Mackowski N, Murphy E, Steenbergen C, Kohr MJ. 2017b. Adenosine a1 
receptor activation increases myocardial protein s-nitrosothiols and elicits protection from 
ischemia-reperfusion injury in male and female hearts. Plos One 12. 
 78 
Sharma NM, Patel KP. 2017. Post-translational regulation of neuronal nitric oxide synthase: 
Implications for sympathoexcitatory states. Expert Opin Ther Tar 21:11-22. 
Shen S, Li XF, Cullen WR, Weinfeld M, Le XC. 2013. Arsenic binding to proteins. Chem Rev 
113:7769-7792. 
Silberman GA, Fan TH, Liu H, Jiao Z, Xiao HD, Lovelock JD, et al. 2010. Uncoupled cardiac 
nitric oxide synthase mediates diastolic dysfunction. Circulation 121:519-528. 
Sips PY, Irie T, Zou L, Shinozaki S, Sakai M, Shimizu N, et al. 2013. Reduction of 
cardiomyocyte s-nitrosylation by s-nitrosoglutathione reductase protects against sepsis-induced 
myocardial depression. Am J Physiol Heart Circ Physiol 304:H1134-1146. 
Skrzypiec-Spring M, Grotthus B, Szelag A, Schulz R. 2007. Isolated heart perfusion according to 
langendorff---still viable in the new millennium. J Pharmacol Toxicol Methods 55:113-126. 
Smith AH, Lingas EO, Rahman M. 2000. Contamination of drinking-water by arsenic in 
bangladesh: A public health emergency. Bull World Health Organ 78:1093-1103. 
Smith AH, Marshall G, Yuan Y, Ferreccio C, Liaw J, von Ehrenstein O, et al. 2006. Increased 
mortality from lung cancer and bronchiectasis in young adults after exposure to arsenic in utero 
and in early childhood. Environ Health Perspect 114:1293-1296. 
Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, et al. 1998. Complete 
remission after treatment of acute promyelocytic leukemia with arsenic trioxide. New Engl J Med 
339:1341-1348. 
States JC, Barchowsky A, Cartwright IL, Reichard JF, Futscher BW, Lantz RC. 2011. Arsenic 
toxicology: Translating between experimental models and human pathology. Environ Health 
Persp 119:1356-1363. 
Stea F, Bianchi F, Cori L, Sicari R. 2014. Cardiovascular effects of arsenic: Clinical and 
epidemiological findings. Environ Sci Pollut Res Int 21:244-251. 
Strijdom H, Chamane N, Lochner A. 2009. Nitric oxide in the cardiovascular system: A simple 
molecule with complex actions. Cardiovasc J Afr 20:303-310. 
Sun J, Picht E, Ginsburg KS, Bers DM, Steenbergen C, Murphy E. 2006. Hypercontractile female 
hearts exhibit increased s-nitrosylation of the l-type ca2+ channel alpha1 subunit and reduced 
ischemia/reperfusion injury. Circ Res 98:403-411. 
Sun JH, Steenbergen C, Murphy E. 2006. S-nitrosylation: No-related redox signaling to protect 
against oxidative stress. Antioxid Redox Sign 8:1693-1705. 
Sutherland FJ, Hearse DJ. 2000. The isolated blood and perfusion fluid perfused heart. Pharmacol 
Res 41:613-627. 
Tan EQ, Gurjar MV, Sharma RV, Bhalla RC. 1999. Estrogen receptor-alpha gene transfer into 
bovine aortic endothelial cells induces enos gene expression and inhibits cell migration. 
Cardiovasc Res 43:788-797. 
 79 
Tan M, Schmidt RH, Beier JI, Watson WH, Zhong H, States JC, et al. 2011. Chronic 
subhepatotoxic exposure to arsenic enhances hepatic injury caused by high fat diet in mice. 
Toxicol Appl Pharmacol 257:356-364. 
Tiso M, Schechter AN. 2015. Nitrate reduction to nitrite, nitric oxide and ammonia by gut 
bacteria under physiological conditions (vol 10, e0119712, 2015). Plos One 10. 
Tseng CH, Chong CK, Tseng CP, Hsueh YM, Chiou HY, Tseng CC, et al. 2003. Long-term 
arsenic exposure and ischemic heart disease in arseniasis-hyperendemic villages in taiwan. 
Toxicol Lett 137:15-21. 
Tseng CH, Huang YK, Huang YL, Chung CJ, Yang MH, Chen CJ, et al. 2006. Arsenic exposure, 
urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic 
villages in taiwan (vol 206, pg 299, 2005). Toxicol Appl Pharm 211:175-175. 
Tsou TC, Tsai FY, Hsieh YW, Li LA, Yeh SC, Chang LW. 2005. Arsenite induces endothelial 
cytotoxicity by down-regulation of vascular endothelial nitric oxide synthase. Toxicology and 
applied pharmacology 208:277-284. 
Tuteja N, Chandra MA, Tuteja R, Misra MK. 2004. Nitric oxide as a unique bioactive signaling 
messenger in physiology and pathophysiology. J Biomed Biotechnol:227-237. 
Valez V, Cassina A, Radi R. 2012. Peroxynitrite formation in nitric oxide-exposed 
submitochondrial particles: Detection and quantitation by a boronic acid-based probe. Free 
Radical Bio Med 53:S28-S29. 
Verdecchia P, Angeli F, Achilli P, Castellani C, Broccatelli A, Gattobigio R, et al. 2007. 
Echocardiographic left ventricular hypertrophy in hypertension: Marker for future events or 
mediator of events? Curr Opin Cardiol 22:329-334. 
von Ehrenstein OS, Guha Mazumder DN, Hira-Smith M, Ghosh N, Yuan Y, Windham G, et al. 
2006. Pregnancy outcomes, infant mortality, and arsenic in drinking water in west bengal, india. 
Am J Epidemiol 163:662-669. 
Wang CH, Jeng JS, Yip PK, Chen CL, Hsu LI, Hsueh YM, et al. 2002. Biological gradient 
between long-term arsenic exposure and carotid atherosclerosis. Circulation 105:1804-1809. 
Wang H, Kohr MJ, Traynham CJ, Wheeler DG, Janssen PML, Ziolo MT. 2008. Neuronal nitric 
oxide synthase signaling within cardiac myocytes targets phospholamban. Am J Physiol-Cell Ph 
294:C1566-C1575. 
Wang M, Crisostomo P, Wairiuko GM, Meldrum DR. 2006. Estrogen receptor-alpha mediates 
acute myocardial protection in females. Am J Physiol Heart Circ Physiol 290:H2204-2209. 
Wang MJ, Crisostomo P, Wairiuko GM, Meldrum DR. 2006. Estrogen receptor-alpha mediates 
acute myocardial protection in females. Am J Physiol-Heart C 290:H2204-H2209. 
Wasserman GA, Liu X, Parvez F, Ahsan H, Factor-Litvak P, van Geen A, et al. 2004. Water 
arsenic exposure and children's intellectual function in araihazar, bangladesh. Environ Health 
Perspect 112:1329-1333. 
 80 
Watson WH, Yager JD. 2007. Arsenic: Extension of its endocrine disruption potential to 
interference with estrogen receptor-mediated signaling. Toxicol Sci 98:1-4. 
Weinhaus AJ, Roberts KP. 2009. Anatomy of the human heart. Handbook of Cardiac Anatomy, 
Physiology, and Devices, Second Edition:59-85. 
Wilcken D. 2012. Physiology of the normal heart. Surgery (Oxford) 30:1-4. 
Willett WC. 2002. Balancing life-style and genomics research for disease prevention. Science 
296:695-698. 
Winslow RL, Walker MA, Greenstein JL. 2016. Modeling calcium regulation of contraction, 
energetics, signaling, and transcription in the cardiac myocyte. Wiley Interdiscip Rev Syst Biol 
Med 8:37-67. 
Wiza C, Nascimento EB, Ouwens DM. 2012. Role of pras40 in akt and mtor signaling in health 
and disease. Am J Physiol Endocrinol Metab 302:E1453-1460. 
Worth RM, Kato H, Rhoads GG, Kagan A, Syme SL. 1975. Epidemiologic studies of coronary 
heart-disease and stroke in japanese men living in japan, hawaii and california - mortality. 
American Journal of Epidemiology 102:481-490. 
Wu Q, Chambliss K, Umetani M, Mineo C, Shaul PW. 2011. Non-nuclear estrogen receptor 
signaling in the endothelium. J Biol Chem 286:14737-14743. 
Zhao X, Feng T, Chen H, Shan H, Zhang Y, Lu Y, et al. 2008. Arsenic trioxide-induced apoptosis 
in h9c2 cardiomyocytes: Implications in cardiotoxicity. Basic Clin Pharmacol Toxicol 102:419-
425. 
Zweier JL, Talukder MA. 2006. The role of oxidants and free radicals in reperfusion injury. 
























Ryne Veenema is originally from upstate New York and graduated from Cornell University 
College of Agriculture and Life Sciences in 2016 with a BS in Environmental and Sustainability 
Sciences. Ryne joined the Kohr Laboratory of Cardiovascular Redox Signaling in 2016 and his 
research is currently focused on the effects of chronic environmental exposures on cardiovascular 
health. 
